JPS6338330B2 - - Google Patents
Info
- Publication number
- JPS6338330B2 JPS6338330B2 JP58029632A JP2963283A JPS6338330B2 JP S6338330 B2 JPS6338330 B2 JP S6338330B2 JP 58029632 A JP58029632 A JP 58029632A JP 2963283 A JP2963283 A JP 2963283A JP S6338330 B2 JPS6338330 B2 JP S6338330B2
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- protein
- column
- propanol
- units
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000000694 effects Effects 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 17
- 102000006992 Interferon-alpha Human genes 0.000 claims description 15
- 108010047761 Interferon-alpha Proteins 0.000 claims description 15
- 150000002337 glycosamines Chemical class 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 239000000356 contaminant Substances 0.000 claims description 2
- 238000004305 normal phase HPLC Methods 0.000 claims description 2
- 238000004007 reversed phase HPLC Methods 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 description 99
- 108010050904 Interferons Proteins 0.000 description 99
- 229940079322 interferon Drugs 0.000 description 89
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 62
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 150000002009 diols Chemical class 0.000 description 9
- 229940047124 interferons Drugs 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N βâMercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- -1 cyanopropyl Chemical group 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex⢠Substances 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010049990 CD13 Antigens Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000004810 partition chromatography Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- FDTUVFSBEYKVAP-UHFFFAOYSA-N formic acid;pyridine Chemical compound OC=O.C1=CC=NC=C1 FDTUVFSBEYKVAP-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013001 matrix buffer Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- YODZTKMDCQEPHD-UHFFFAOYSA-N thiodiglycol Chemical compound OCCSCCO YODZTKMDCQEPHD-UHFFFAOYSA-N 0.000 description 1
- 229950006389 thiodiglycol Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
ã¿ã³ãã¯è³ªã®ç²Ÿè£œã¯é·ãéããããååŠã«ãã
ãïŒã€ã®åé¡ã§ãã€ãããããŸã§çšãããŠããæ
è¡ã®äŸã¯ãæ²æ®¿ãã²ã«éãã€ãªã³äº€æã¯ããã
ã°ã©ãã€ãŒãã²ã«é»æ°æ³³åã芪åæ§ã¯ãããã°ã©
ãã€ãŒããã³è¿°ã¹ãã«ã¯å€éããä»ã®æ¹æ³ã§ã
ãã 倩ç¶ã«ç£åºããã極ããŠäœæ¿åºŠã§çç©åŠçè©Šæ
äžã«ååšããé«ååéã®ã¿ã³ãã¯è³ªãåé¢ããã
ãšããèšç»ã¯ãåè¿°ã®æè¡ã®æ€å®ïŒassayïŒãå©
çšããå€å·¥çšæ³ã§ãã€ããå€æ°ã®ãã®ãããªå Žå
ã«ãããŠã極ããŠå€§éã®ç²è£œåºçºç©è³ªãèç©ãã
ã³åŠçããªããŠã¯ãªãããããã«ã¯ç²Ÿè£œåŸã®å·¥çš
ã«ãããŠå€éã®çæç©ã倱ãªãããããé«ãçµè²»
ãšéåžžå€ãã®åŽåãèŠããã åé¡ã®ïŒã€ã®é©åœãªã±ãŒã¹ã¯ã€ã³ã¿ãŒããšãã³
ïŒinterferonïŒãåé¢ããã³ç¹åŸŽã¥ããå€æ°ã®è©Š
ã¿ã®æŽå²ã§ãããã¢ã€ã¶ãã¯ïŒIsaacsïŒããã³ãª
ã³ãã³ãã³ïŒLindenmannïŒã«ããæåã®çºèŠä»¥
æ¥ã20幎ã«ããã€ãŠå šäžçã®ç 究è éã¯ã€ã³ã¿ãŒ
ããšãã³ããããçœè¡çåã§ããããšãŸãç·ç¶èœ
现èåã§ããããšãå質ãªãããããšããŠããã®
ç¹å®ã®çç©åŠçãŸãã¯ååŠçæ§è³ªãç¹åŸŽã¥ãäžã€
åå®ã§ããã®ã«ååãªéã§åé¢ããããšãããã
äžæåã«çµã€ãã ã¢ã€ã¶ãã¯ããã³ãªã³ãã³ãã³ã®ã€ã³ã¿ãŒããš
ãã³ãçšããå ã®ç 究ã«é¢ããç±³åœç¹èš±ç¬¬
3699222å·ã«ãããŠã掻æ§ç©è³ªã®ç²Ÿè£œã¯ç¡«é žã¢ã³
ã¢ããŠã ã®æ²æ®¿ããã³ããã«åŒãç¶ãéæã«éå®
ãããŠããããã®ãããªæ¹æ³ã¯æ¯èŒçéç¹å®çã§
ãããããããŠããã«ãã€ãŠåŸãããçæç©ã¯ãª
ã極ããŠç²è£œç¶æ ã§ããã ã€ã³ã¿ãŒããšãã³ã粟補ããå€å·¥çšæ³ã¯ç±³åœç¹
蚱第3414651å·ã«é瀺ãããŠããããã®å€å·¥çšæ³
ã¯éæ¶è³ªã¢ã«ããâã·ãªã±ãŒãäžã®éžæçåžçã
ãšãŠçŽ ãŸãã¯ããªã·ã¢ããŒãã®æº¶æ¶²ãçšãã溶
é¢ãããã«HCl氎溶液ã次ãã§NaOHãçšããæ
ãŸãªãã¿ã³ãã¯è³ªã®æ²æ®¿ãæ°Žæ··åæ§æº¶åªãããšã
ã°ã¡ã¿ããŒã«ããšã¿ããŒã«ãŸãã¯ã¢ã»ãã³ãçšã
ãã€ã³ã¿ãŒããšãã³ã®å¡©åºæº¶æ¶²ããã®æ²æ®¿ããã
ã³æåŸã«ïŒâãžãšãã«ã¢ãããšãã«âã»ã«ããŒã¹
ã®ãããªé°ã€ãªã³äº€ææš¹èã«ããå溶解ããã€ã³
ã¿ãŒããšãã³ã®ã¯ãããã°ã©ãã€ãŒãçšããŠãã
ã®æ¯æŽ»æ§ããã®å šããã»ã¹ã«ãã6000åã«é«ãã
ãããšç€ºãããã€ã³ã¿ãŒããšãã³ãçæãããäŸ
瀺ãããç¹å®ã®ã€ã³ã¿ãŒããšãã³ã¯ããšã³ãšãµã«
ã®ã€ã³ã¿ãŒããšãã³ã§ãã€ãã ã»ãã®ç²Ÿè£œæ³ã¯ç±³åœç¹èš±ç¬¬3975344å·ã«æ瀺ã
ããŠãããããã§ã¯çŽ°èå¹é€ã®å¹å°ããèªå°ãã
ãç²è£œã®äººã®ç·ç¶èœçŽ°èã®ã€ã³ã¿ãŒããšãã³æº¶æ¶²
ãåºåå¯åºŠåŸé ã®è¶ é å¿åé¢ã«ãã€ãŠç²Ÿè£œãããŠ
ããããã®æè¡ã¯ã»ãã¢ããã¯ã¹ïŒSephadexïŒ
â100ãçšããæ®éã®ã«ã©ã ã°ãããã°ã©ãã€
ãŒã§åŸãããããé«ãåçããã³ç²Ÿè£œãäžããã
ãšã瀺ãããã ã€ã³ã¿ãŒããšãã³ã®ç²Ÿè£œããã³ç¹æ§ã¥ãã«é¢ã
ãæè¿ã®ç§åŠæç®ã¯ã次ã®ããã«èŠçŽããããšã
ã§ããïŒ KnightãE.ãProc.Natl.Acad.Sci.UAS 73ã
520âïŒïŒ1976ïŒïŒ TošrmašãE.T.et al.ãJ.Biol.Chem.251ã4810
âïŒïŒ1976ïŒïŒ BridgenãP.J.et al.ãJ.Biol.Chem.252ã6585
âïŒïŒ1977ïŒïŒ DeMaeyerâGuignardãJ.et al.ãNature
271ã622âïŒïŒ1978ïŒïŒ KawakitaãM.et al.ãJ.Biol.Chem.253ïŒ598
â602ïŒ1978ïŒïŒ BertholdãW.et al.ãJ.Biol.Chem.253ã5206
â11ïŒ1978ïŒïŒ JankowskiãW.J.et al.ãJ.Virology 16ã
1124â30ïŒ1975ïŒïŒ DaveyãM.W.et al.ãJ.Biol.Chem.251ã7620
âïŒïŒ1976ïŒïŒChadhaãK.C.et al.ã
Biochemistry 17ã196â200ïŒ1978ïŒã äžèšã®æç®ã®ããã€ãã¯ããŠã¹ãŸãã¯äººã®ã€ã³
ã¿ãŒããšãã³ãå質ã«ç²Ÿè£œãããšè¿°ã¹ãŠãããã
ã¿ã³ãã¯è³ªã®å質æ§ã®å€å žç蚌æãäžããããŠã
ããããããã¯èšèŒãããŠããçŽç²ãšããããå
åç©ã®æ§è³ªã¯èšèŒãããŠããªãã ã¿ã³ãã¯è³ªã®ç²Ÿè£œã«é«æ§èœæ¶²äœã¯ãããã°ã©ã
ã€ãŒïŒHPLCïŒã䜿çšããããšã¯äžè¬ã«æè¡çã«
ç¥ãããŠããããããã®åèæžã¯ç¹å®çã«ã¿ã³ã
ã¯è³ªã®ç²Ÿè£œã«ãããã€ãªã³äº€æããã³å€§ããæé€
åã®ã«ã©ã ãèšèŒããŠãããããšãã°ã
RegnierãF.E.et al.ãJ.Chromatog.Sci.14ã316
â20ïŒ1976ïŒããã³ChangãS.âH.et al.ãAnal.
Chem.48ã1839â45ïŒ1976ïŒåç §ã éçžïŒrcverse phaseïŒåé ã¯ãããã°ã©ãã€
ãŒã«ããããªã¯ããœã«ãïŒLichrosorbïŒRPâ18
ïŒãªã¯ã¿ãã·ã«çµåã·ãªã«åŸ®ç²åã«ã©ã ïŒã®äœ¿çš
ã¯ãβâãšã³ãã«ãã€ã³ã®ãããªããããã粟補
ããããã«æåãããã®ã§ãããããšãã°ã
RubinsteinãM.et al.ãProc.Natl.Acad.Sci.ã
USA 74ã4969â72ïŒ1977ïŒããæåŸã«ãããŠã¹ã®
Ehrlichè ¹æ°Žçã®è «ç现èããã®ã€ã³ã¿ãŒããšã
ã³ã®ïŒçš®ïŒååéïŒ33000ã26000ããã³20000ïŒ
ã®éšåçç¹æ§ã¥ãã¯ãCabrerãB.et al.ãJ.Biol.
Chem.254ã3681âïŒïŒ1979ïŒã«èšèŒãããŠããã ãŠã·çŽ°èMDBKã®å Žåãæ¯æŽ»æ§0.9Ã108ã4.0
Ã108åäœïŒmgã¿ã³ãã¯è³ªãæãããã现èç³»
AG1732ã®å Žåãæ¯æŽ»æ§ïŒÃ106ã4.0Ã108åäœïŒ
mgã¿ã³ãã¯è³ªãæããååéçŽ16000±1000ãçŽ
21000±1000ã§ãããã¢ããç³åãïŒåååœãïŒ
æ®åºæªæºã§ãããé çžããã³ïŒãŸãã¯ïŒéçžé«é
液äœã¯ãããã°ã©ãã€ãŒã«ãããŠåäžã®ããŒã¯ã
瀺ããšãšãã«ãããã·ã«ç¡«é žãããªãŠã âããªã¢
ã¯ãªã«ã¢ããã²ã«é»æ°æ³³åïŒSDSâPAGEïŒã§å
äžãã³ãã瀺ãå質ã¿ã³ãã¯è³ªã§ããããçœè¡ç
ã€ã³ã¿ããšãã³ãå«æããããã·ã«ç¡«é žãããªãŠ
ã ããã³éã€ã³ã¿ããšãã³æŽ»æ§ã¿ã³ãã¯è³ªå€Ÿéç©
ãå®è³ªçã«å«ãŸãªãããšãç¹åŸŽãšãããããçœè¡
çã€ã³ã¿ããšãã³æåæ§çŸæ£æ²»ççšå»è¬çµæç©ã«
é¢ããã æ¬çºæã®å»è¬çµæç©ã«ãããããçœè¡çã€ã³ã¿
ããšãã³ã¯ããã®å»è¬ãšããŠéèŠãªç©è³ªã®ååŠç
ç¹æ§ã¥ããåããŠå¯èœã«ããçŽãããªã€ã³ã¿ããš
ãã³ãååãªéã§æäŸããæ°èŠè£œé æ¹æ³ã«ããåŸ
ããããæ¬çºæã®çµæç©ã«ãããã€ã³ã¿ãŒããšã
ã³ã®ååŠçç¹æ§ã¥ããå¯èœã«ããããšã¯ããã®ç©
質ã®éçºã«ãããææãªé²æ©ãè¡šããããªããª
ããããã«ãããæ®éã®ããããåææ³ã«ããã
æãã¯ã€ã³ã¿ãŒããšãã³ã¢ããé žé åã«çžåœãã
DNAãåæãããããŠãã®ãããªDNAãé©åœãª
ææ©äœã奜ãŸããã¯ãã¯ããªã¢äžã«ãDNAâçµ
æãæè¡ã«ããå°å ¥ããããšã«ãã€ãŠãã€ã³ã¿ãŒ
ããšãã³ãåæã§ããããã§ããã次ãã§ãçã
ãææ©äœã¯ã€ã³ã¿ãŒããšãã³ãçæããèœåãæ
ããããã¯çºé µæè¡ãå¿çšããŠåæ¥çãªã¬ãã«ã§
åŸæ¥ãŸããªååç©ã®äŸ¿å©ãªæºãæäŸããããã«èŠ
æš¡ã倧ããããããšãã§ããã ã€ã³ã¿ãŒããšãã³ãå質ãªã¿ã³ãã¯è³ªãšããŠè£œ
é ããæ¹æ³ã¯ãäžçŽãªç¶æ ã®ã€ã³ã¿ãŒããšãã³ã®
氎溶液ãã·ã¢ããããã«ãã·ã¯ãããã·ã«ãããš
ãã«ããªã¯ãã«ããªã¯ã¿ãã·ã«ãŸãã¯ã°ãªã»ãªã«
åºãçµåããå€å質ã·ãªã«ã®ãããªãã¯ã¹ã®ç·©è¡
液ã§å¹³è¡¡åããã«ã©ã ã«ãé«é液äœã¯ãããã°ã©
ãã€ãŒïŒHPLCïŒã®æ¡ä»¶äžã«éããŠã€ã³ã¿ãŒããš
ãã³ãã«ã©ã äžã«åžçããããã®åŸãã®ã€ã³ã¿ãŒ
ããšãã³ãå¢å ããåŸé ãŸãã¯æžå°ããåŸé ã®æ°Ž
æ§ã®æ°Žæ··åæ§æº¶åªã§æº¶é¢ãããããŠã€ã³ã¿ãŒããš
ãã³ã溶åºæ¶²ã®éžå®ãã©ã¯ã·ãšã³äžã«é«çŽåºŠã®ç¶
æ ã§åŸãããšãããªãã ã€ã³ã¿ãŒããšãã³ãå質ã®ã¿ã³ãã¯è³ªãšããŠè£œ
é ããæ¹æ³ã®äŸãšããŠã次ã®å·¥çšã®çµã¿åããã
ããªãæ¹æ³ããããããšãã§ããïŒ (A) äžçŽãªç¶æ ã®ã€ã³ã¿ãŒããšãã³ã®æ°Žæº¶æ¶²ãã
ç·©è¡æ¶²ã§å¹³è¡¡åãããªã¯ãã«çµåã·ãªã«ã®ãã
ãªãã¯ã¹ã®ã«ã©ã ã«ãé«æ§èœæ¶²äœã¯ãããã°ã©
ãã€ãŒæ¡ä»¶äžã«éããŠè©²ã€ã³ã¿ãŒããšãã³ã該
ã«ã©ã äžãžåžåããããã®åŸè©²ã€ã³ã¿ãŒããšã
ã³ã該ã«ã©ã ããå¢å ããåŸé ã®æ°Žæ§ã®ç·©è¡ã
ãæ°Žæ··åæ§æº¶åªã§æº¶é¢ãããããŠè©²ã€ã³ã¿ãŒã
ãšãã³ã該溶åºæ¶²ã®éžå®ãã©ã¯ã·ãšã³äžã«é«çŽ
床ã®ç¶æ ã§åŸïŒ (B) å·¥çšïŒ¡ã«ãããŠåŸãããéžã°ããã€ã³ã¿ãŒã
ãšãã³ã®ãã©ã¯ã·ãšã³ããç·©è¡æ¶²ã§å¹³è¡¡åãã
ã°ãªã»ãªã«çµåããã·ãªã«ã®ãããªãã¯ã¹ã®ã«
ã©ã ã«éããŠè©²ã€ã³ã¿ãŒããšãã³ã該ã«ã©ã äž
ãžåžåããããã®åŸè©²ã€ã³ã¿ãŒããšãã³ã該ã«
ã©ã ããæžå°ããåŸé ã®æ°Žæ§ã®ç·©è¡ããæ°Žæ··å
æ§æº¶åªã§æº¶é¢ãããããŠã€ã³ã¿ãŒããšãã³ãæ
確ãªäž»ããŒã¯ãšããŠè©²æº¶åºæ¶²ã®éžå®ãã©ã¯ã·ãš
ã³äžã«é«çŽåºŠã®ç¶æ ã§åŸïŒ (C) å·¥çšïŒ¢ã«ãããŠåŸããã該æ確ãªäž»ããŒã¯ã®
ïŒã€ã«çžåœããã€ã³ã¿ãŒããšãã³ã®éžå®ãã©ã¯
ã·ãšã³ã®ç·©è¡æº¶æ¶²ããç·©è¡æ¶²ã§å¹³è¡¡åãããªã¯
ãã«çµåã·ãªã«ã®ãããªãã¯ã¹ã®ã«ã©ã ã«ãé«
æ§èœæ¶²äœã¯ãããã°ã©ãã€ãŒæ¡ä»¶äžã«éããŠè©²
ã€ã³ã¿ãŒããšãã³ã該ã«ã©ã äžãžåžåãããã
ã®åŸè©²ã€ã³ã¿ãŒããšãã³ã該ã«ã©ã ããæ°Žæ§ã®
ç·©è¡ããæ°Žæ··åæ§æº¶åªã§æº¶é¢ãããããŠã€ã³ã¿
ãŒããšãã³ãåäžã®æ確ãªããŒã¯ãšããŠè©²æº¶åº
液ã®éžå®ãã©ã¯ã·ãšã³äžã«å質ãªã¿ã³ãã¯è³ªã®
ç¶æ ã§åŸããããŠãå¿ èŠã«å¿ããŠãå·¥çšïŒ£ã®æ
äœãå埩ããŠç©¶æ¥µã®å質æ§ãéæããã äžèšã®ãããªå·¥çšã«ããããªã¯ãã«ãŸãã¯ã°ãª
ã»ãªã«å€æ§å€å質ã·ãªã«ã®åŸ®ç²åã®ã«ã©ã ïŒç²åºŠ
ïŒ10ÎŒïŒå¹³åå倧ããïŒ100â«ïŒãšããŠã¯ãã¢ã¡
ãªã«åè¡åœããŠãŒãšãŒã¯å·ãšã«ã ã¹ããªãŒãã®
EMã©ãã©ããªãŒãºïŒEM Laboratories of
ElmsfordãN.Y.ãUSAïŒãããåæšLichrosorb
RPâïŒããã³LichrosorbãžãªãŒã«ãšããŠå ¥æã§
ããååãäŸç€ºã§ãããåçã®ãªã¯ãã«å€æ§å€å
質ã«ã©ã ïŒChromegabond âïŒãšããŠèå¥ã
ããïŒã¯ãã¢ã¡ãªã«åè¡åœããŠãŒãžã€ãŒãžãŒå·ã
ãŒã«ãã³ã®E.Sã€ã³ãã¹ããªãŒãºïŒE.S.
IndustriesãMarltonãN.J.ãUSAïŒããå ¥æã
ãããšãã§ããã åè¿°ã®ã«ã©ã ãå©çšãã䟿å©ãªé«å§æ¶²äœã¯ãã
ãã°ã©ãã€ãŒç³»ã¯ç±³åœç¹èš±ç¬¬4116046å·ã«èšèŒã
ããŠããã ãã®æ¹æ³ãå®æœããå ŽåãäžçŽãªé«ååéã®ã
ãããã®ã奜ãŸããã¯åé¡ã®ã¿ã³ãã¯è³ªã®æ§è³ªãš
é©åããPHã«ãããç·©è¡æ°Žæº¶æ¶²äžã®æº¶æ¶²ãã·ãªã«
ã®ãããªãã¯ã¹ã®ã«ã©ã ã«éããéåžžããã®æäœ
ã¯å å§äžã«ã奜ãŸããã¯çŽ50ãçŽ5000psiïŒ3.4ã
340æ°å§ïŒã®ç¯å²ã«ãããŠå®æœãããã¿ã³ãã¯è³ª
ãã«ã©ã ã«åžçããã次ãã§æ°Žãšæ··åæ§ã®æº¶åªã®
åŸé ãçšããŠéžæçæ¹åŒã§ç¶ç¶ããŠæº¶é¢ãããã
ã®ç®çã«é©ããæ°Žæ··åæ§ã®æº¶åªã®äŸã¯ãã¢ã«ã«ã
ãŒã«ãããšãã°ïœâãããããŒã«ãïŒâãããã
ãŒã«ããšã¿ããŒã«ãã¡ã¿ããŒã«ãïœâãã¿ããŒã«
ãŸãã¯ç°åŒãšãŒãã«ãããšãã°ãžãªããµã³ã§ã
ãã溶é¢æ¶²ã®åå¥ã¯ããã©ã¯ã·ãšã³ã»ã³ã¬ã¯ã¿ãŒ
ã䜿çšããããèªäœç¥ãããæ¹æ³ã«ãããåãã©
ã¯ã·ãšã³äžã®ã¿ã³ãã¯è³ªå«éããé«æ床ã§åäœã
ãããããã¢ãã¿ãŒã§åæã«ç£èŠããããšã«ãã€
ãŠéæããããã®ç®çã«é©åœãªç³»ã¯Bohlen et
al.ãAnal.Biochem.67ã438ïŒ1975ïŒã«é瀺ãããŠ
ããããŸããã¿ãŒã²ããã»ã¿ã³ãã¯è³ªã®ååšãé©
åœãªçç©æ€å®ã«ããç£èŠããããšã奜ãŸããã äž¡æ¹ã®ã«ã©ã ïŒãé çžãåé ã¯ãããã°ã©ãã€
ãŒã®ããã®ã«ã©ã ããã³éçžã¯ãããã°ã©ãã€ãŒ
ã®ããã®ã«ã©ã ïŒãçšãããã©ãããããããå Ž
åã©ã®é åºãéžã¶ãã«ã€ããŠã®æ±ºå®ã¯ã倧éšå粟
補ãã¹ãã¿ã³ãã¯è³ªã®æ§è³ªã«äŸåãããããšã
ã°ã人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®ç¹å®ã®å Žå
ã«ãããŠããŸãäžçŽãªã€ã³ã¿ããšãã³æº¶æ¶²ããPH
7.5ã®ç·©è¡æ¶²ãæãŸããã¯1Mã®é ¢é žãããªãŠã â
é ¢é žç³»ãçšãããªã¯ãã«çµåã·ãªã«ãããªãã¯ã¹
ã«ã©ã ã«éããŠåé¢ããå¢å ããæ¿åºŠåŸé ã®ïœâ
ãããããŒã«ã§æº¶é¢ãã次ãã§éãã掻æ§ãªãã©
ã¯ã·ãšã³ã0.1Mã®é ¢é žãããªãŠã äžã®ã°ãªã»ãª
ã«çµåã·ãªã«ãããªãã¯ã¹ã«ã©ã ã«éããäœäžã
ãïœâãããããŒã«ã®åŸé ã§æº¶é¢ããæåŸã«åé¢
ããã€ã³ã¿ãŒããšãã³æåããªã¯ãã«çµåã·ãªã«
ãããªãã¯ã¹ã«ã©ã ã«ãçŽ4.0ã®ç·©è¡æ¶²ã®PHã奜
ãŸããã¯1Mã®ããªãžã³â2Mã®ã®é žç³»ãçšããŠé
ãããããŠå¢å ããïœâãããããŒã«ã®åŸé ã§æº¶
é¢ããããšã«ãã€ãŠãæè¯ã®çµæãéæãããã
ãšãããã€ãããã®ããã«ããŠã人ã®çœè¡çã®ã€
ã³ã¿ãŒããšãã³ã®ïŒã€ã®å¥ã ã®åœ¢æ ïŒÎ±ãβãã
ã³Î³ïŒã®åã ã¯å質ãªã¿ã³ãã¯è³ªãè¡šããå¥ã ã®
éãããŒã¯ã«åå²ããããšãã§ããã第ïŒã®ãªã¯
ãã«çµåã·ãªã«ãããªãã¯ã¹ã¯ãããã°ã©ãã€ãŒ
å·¥çšã«å¯Ÿããå¹å°ãçšããŠåºçºããå šäœã®ç²Ÿè£œ
ã¯ã60000ã80000åã§ãã€ãããã°ãªã»ããŒã«çµ
åã·ãªã«ãããªãã¯ã¹ã®ã¯ãããã°ã©ãã€ãŒå·¥çš
ãéãã环ç©åçã¯30ã50ïŒ ã®ç¯å²ã§ãã€ãã 人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®ç²Ÿè£œæ³ã®ç¹å®
ã®æ æ§ã«ãããŠãå·¥çšïŒ¢ããã®éžå®ããŒã¯ãã©ã¯
ã·ãšã³ãéããïœâãããããŒã«ãïœâãããµã³
ã§æœåºããŠé€å»ãããããŠåŸ®éã®ïœâãããµã³ã
å·¥çšïŒ£ãžé²ãåã«æ°Žçžããé€å»ããã ãã®æ°èŠæ¹æ³ã«ããåŸãããå質ãªäººã®çœè¡ç
ã®ã€ã³ã¿ãŒããšãã³ã®çš®ã®åã ã¯ãåè¿°ã®HPLC
ã«ã©ã äžã®éãããŒã¯ãšãïŒâã¡ã«ã«ãããšã¿ã
ãŒã«ã®ååšäžã®ããã·ã«ç¡«é žãããªãŠã
ïŒNaDodSO4ïŒããªã¢ã¯ãªã«ã¢ããã²ã«é»æ°æ³³å
äžã®åäžã®çã垯ãšã瀺ããããã®ã²ã«ãæœåºã
ããšãã¿ã³ãã¯è³ªåž¯ãšäžèŽããæãŠã€ã«ã¹æŽ»æ§ã®
åäžã®éãããŒã¯ãåŸãããããã®çŽç²ãªã€ã³ã¿
ãŒããšãã³ã®çš®ã®æ¯æŽ»æ§ã¯ãMDBKã®çã®çŽ°è
ã§çŽ0.9ã4.0Ã108ã®ç¯å²ã§ããããããŠAg1732
ã®äººã®çŽ°è系統ïŒhuman cell lineïŒã§çŽïŒÃ106
ãïŒÃ108ã§ããããšãããã€ããåã€ã³ã¿ããš
ãã³çš®ã®æ¯æŽ»æ§ãè¡šïŒã«ç€ºãããã®æ¯æŽ»æ§ã¯ããŠ
ã€ã«ã¹ã®çŽ°èå€æ§å¹æã«åºã¥ãã€ã³ã¿ããšãã³ã®
æãŠã€ã«ã¹æŽ»æ§ã®æž¬å®æ¹æ³ã§ããCPEåæïŒçŽ°
èå€æ§å¹æé»æ¢æ€å®ïŒã«ãã枬å®ããã çšãã现èç³»ã¯ãŠã·çŽ°èMDBKããã³ãã现
èAG1732ã§ããããããã¯ã€ãŒã°ã«ã®æå°å¿ é
åå°MEMâ10ã«åå±€å¹é€ãããŠãããã®ã§ã
ããçšãããŠã€ã«ã¹ã¯ãããŠã¹ïŒ¬çŽ°èã®åå±€å¹é€
äžã«çè²ãããMEMâ10äžã«åçµä¿åããæ°Žç±
æ§å£å çãŠã€ã«ã¹ïŒVSVïŒã§ããã被éšã€ã³ã¿
ããšãã³ãµã³ãã«ã¯MEMâ10ãçšããŠåžéã
ãã ãã€ã¯ãã¿ã€ã¿ãŒãã¬ãŒãã«ãŸãã€ã³ã¿ããšã
ã³ãµã³ãã«ãæ³šå ¥ããMEMâ10äžã®MDBKã
ãã³AG1732现èç³»ãå ããVSVãæ¥çš®ãããã
ãŠ37âã§16æéã€ã³ããŠããŒããããVSVã«ã
ã现èå€æ§ã50ïŒ æå¶ããã€ã³ã¿ããšãã³æ¿åºŠ
ïŒID50ïŒã1UïŒmlãšãããã®å€ã«åžéåçãä¹
ããæŽã«åæã«æž¬å®ããæšæºã€ã³ã¿ããšãã³ã®
ID50ã瀺ãæ¿åºŠïŒïŒµïŒmlïŒã«åºã¥ãè£æ£ãè¡ãªã€
ãŠã€ã³ã¿ããšãã³ãµã³ãã«ã®æãŠã€ã«ã¹æŽ»æ§ãã€
ãŸãè¡šïŒã«ç€ºãæ¯æŽ»æ§ãåŸããååéã¯è¡šïŒã«èŠ
ãããããã«çŽ16000ã21000ã®ç¯å²ã§ãã€ããã¢
ããé žåæã®çµæã¯è¡šïŒã«èŠçŽãããŠããã ã€ã³ã¿ãŒããšãã³é¡ã¯æãŠã€ã«ã¹æŽ»æ§ãå¶ç掻
æ§ãçºçé»å®³æŽ»æ§ããã³å ç«æå¶æŽ»æ§ã瀺ããã
ãããã®æŽ»æ§ã¯ã人ã®ã€ã³ã¿ãŒããšãã³ãïŒïŒ ã
ãå°ãªãæ¯èŒçç²è£œã®è£œå€ãçšããŠïŒã10Ã106
åäœïŒæ¥ãçšããèšåºã¬ãã«ã«ãããŠããåŸãã
ããæ¬çºæã®ïŒã€ã®é¢ã§ãã粟補ãããå質ãªã€
ã³ã¿ãŒããšãã³é¡ã¯ãåŸæ¥çšããããç²è£œã®è£œå€
ãšåãæ¹æ³ã§æäžéã調æŽããŠæãã¬ãã«ã®ã€ã³
ã¿ãŒããšãã³åäœãäžããããã«ããŠäœ¿çšããã
ãšãã§ãããåã ã®çš®ã¯ãã®ãŸãŸäœ¿çšããããšã
ã§ããæãã¯ãã®ãããªçš®ã®ïŒçš®ä»¥äžã®æ··åç©ã
䜿çšããããšãã§ããããã®ãããªæ··åç©ã¯åé¢
ããçš®ãæãããã«æ··åããããšã«ãã€ãŠåŸãã
ãšãã§ããæãã¯ã€ã³ã¿ãŒããšãã³ã®å¹Ÿã€ãã®çš®
ãååšããããéã€ã³ã¿ãŒããšãã³ã®æŽ»æ§ãªã¿ã³
ãã¯è³ªãååšããªããšããã§ç²Ÿè£œãåæ¢ããçµæ
ç©ãå質ãªã€ã³ã¿ãŒããšãã³ã¿ã³ãã¯è³ªã®æ··åç©
ã§ããããã«ããããšã«ãã€ãŠãåŸãããšãã§ã
ãã ã€ã³ã¿ãŒããšãã³ã®ç£çã®èªå°ãã€ã³ã¿ãŒããš
ãã³ã®åææ¿åºŠããã³ã²ã«éãå«ãã€ã³ã¿ãŒã
ãšãã³ã®åå¥ã¯ãã®åéã§ããç¥ãããæ¹æ³ãçš
ããŠéæããããšãã§ãããäžçŽãªç¶æ ã®ã€ã³ã¿
ãŒããšãã³ã®æ°Žæº¶æ¶²ãçæãããããã®æäœã¯æ¬
çºæã®äžéšåã§ã¯ãªãã æ¬çºæã®çµæç©ã«ãããã€ã³ã¿ããšãã³ã®è£œé
ã以äžã®äŸã«ãããã詳现ã«ç€ºãã å®æœäŸ ïŒ æ£åžžã®æäŸè ïŒdonorïŒããã®å質ãªäººã®çœè¡
çã®ã€ã³ã¿ãŒããšã㳠 ã€ã³ã¿ãŒããšãã³ã®è£œé ã«ãŒã€ã³ïŒ10mgïŒmlïŒãå«æããè¡æž äžå«æ
å°å¿ é å¹å°äžã§ãæ£åžžã®æäŸè ã®è¡æ¶²ããã®ã
ãçœè¡çïŒ107现èïŒmlïŒããããŠãŒã«ãã¹ã«
ïŒNewcastleïŒç æ°ãŠã€ã«ã¹ïŒ15è¡çåéå
äœïŒmlïŒãš16æéå¹é€ããããšã«ãã€ãŠãã€ã³
ã¿ãŒããšãã³ãç£çãããã5000åäœïŒmlã®å¹³
åã®ã€ã³ã¿ãŒããšãã³ã®å䟡ãåŸããçšããæ
äœã¯MogensenãK.E.et al.ãPharmacology
and Therapeutics ã1977ã369â381ïŒ
WheelockãE.F.ãJ.Bacteriol.92ã1415â1421
ïŒ1966ïŒããã³CantellãK.et al.ãAppl.
Microbiol.22ã625â628ïŒ1971ïŒã«å ±åããã
ãã®ãå€å°å€æŽãããã®ã§ãã€ããã€ã³ã¿ãŒã
ãšãã³ã®å䟡ã¯ã现èå€æ§å¹æâé»æ¢æ€å®ã«ã
ã€ãŠæž¬å®ãããã®æ€å®ã¯16æé以å ã§å®æœãã
ããšãã§ããããã¹ãŠã®ã€ã³ã¿ãŒããšãã³ã®å
䟡ã¯åç §åäœïŒmlã§è¡šãããããã¯ãã·ãšã
ã«ã»ã€ã³ã¹ã·ããŠãŒãã»ãªãã»ãã«ã¹ãthe
National Institute of HealthïŒUSAïŒãã«ãã
æäŸããã人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®ã
ãã®åç §æšæºã«å¯ŸããŠè£æ£ããã  ã€ã³ã¿ãŒããšãã³ã®æ¿åºŠããã³åæã®åç» ç¹ã«ç€ºããªããããããããã®æäœã¯ïŒãïŒ
âã§å®æœãããå¹é€ã®çµãã«ãããŠã现èãã
ã³æ®å±ïŒdebrisïŒãäœéé å¿åé¢ïŒ15åã500
ÃïœïŒã«ããé€å»ãããã«ãŒã€ã³ãHClã§PH
4.0ã«é žæ§åããããšã«ãã€ãŠæ²æ®¿ãããïŒæ
éåŸããã®æ··åç©ãé å¿åé¢ïŒ10åã12000Ã
ïœïŒãããããŠãã¬ãããå»æ£ãããäžå±€ïŒ10
ïŒã15ïŒ ïŒïŒ·ïŒïŒ¶ïŒã®ããªã¯ããé ¢é žã«èª¿æŽ
ãããïŒæéåŸãæ²æ®¿ãé å¿åé¢ïŒ10åã
12000ÃïœïŒã«ããéãããããŠ50mlã®0.1Mã®
NaHCO3äžã«å溶解ãããããªãã³Ãâ100
ïŒ0.5ïœïŒãå ãã次ãã§é ¢é žïŒ1.5mlïŒããã
ãŸããªãã滎ã å ããããã®æ··åç©ãïŒâã§ïŒ
æéã次ãã§â20âã§16æé貯èµããã次ãã§
ããã解åããé å¿åé¢ïŒ10åã17000ÃïœïŒ
ããããã¬ãããå»æ£ããäžå±€ãïŒïŒ ã®ããªã¯
ããé ¢é žã«èª¿æŽãããïŒæéåŸããã®æ··åç©ã
é å¿åé¢ïŒ10åã12000ÃïœïŒãããæ²æ®¿ç©ã
éãããããŠïŒmlã®0.5ã¢ã«ã®NaHCO3äžã«å
溶解ããã  ã²ã«é å°¿çŽ ïŒ1.5ïœïŒãã€ã³ã¿ãŒããšãã³ã®æ¿çž®ç©
ã«å ãããããŠãã®æº¶æ¶²ã4Mã®å°¿çŽ ïŒ0.1Mã®
é ¢é žãããªãŠã ã®ç·©è¡æ¶²ã§åãã€ãŠå¹³è¡¡åãã
ã»ããšããã¯ã¹ïŒSephadexïŒïŒ§â100ã®åŸ®çŽ°ç²
åã®ã«ã©ã ïŒ2.6Ã90cmïŒã«éããããã®ã«ã©
ã ã4Mã®å°¿çŽ ïŒ0.1Mã®é ¢é žãããªãŠã ãPH
7.5ã§ã宀枩ã«ãããŠ0.5mlïŒåã®æµéã§æº¶é¢ã
ãã12.5mlã®ãã©ã¯ã·ãšã³ãéãããã€ã³ã¿ãŒ
ããšãã³ã®æŽ»æ§ã¯ãã©ã¯ã·ãšã³19â23äžã«æº¶åº
ãããã  é«æ§èœæ¶²äœã¯ãããã°ã©ãã€ãŒ ã»ãã¢ããã¯ã¹ïŒ§â100ã®è©Šéšã®ãã©ã¯ã·ãš
ã³19â23ãåãããçŽæ¥ãã³ããçµãŠãªã¯ããœ
ã«ãïŒLichrosorbïŒRPâïŒã«ã©ã ïŒ10ÎŒã4.6
Ã250mmïŒã«éããããã®ã«ã©ã ã¯0.01ïŒ
ïŒïŒ¶ïŒïŒ¶ïŒã®ããªãžã°ãªã³ãŒã«ãå«æããïŒã¢
ã«ã®é ¢é žãããªãŠã ç·©è¡æ¶²ïŒPH7.5ïŒã§åãã€
ãŠå¹³è¡¡åãã次ãã§çŽç·ã®æ¿åºŠåŸé ã®ïœâãã
ãããŒã«ã§åäžç·©è¡æ¶²äžã§0.25mlïŒåã®æµéã§
溶é¢ãããïŒæéãïŒã20ïŒ ïŒïŒæéã20ã40
ïŒ ïŒïŒ¶ïŒïŒ¶ïŒãã0.75mlã®ãã©ã¯ã·ãšã³ãéã
ããã€ã³ã¿ãŒããšãã³ã¯ãã©ã¯ã·ãšã³23ã40
ã25ã30ïŒ ïŒïŒ¶ïŒïŒ¶ïŒã®ïœâãããããŒã«ãäž
ã«æº¶åºãããã ã€ã³ã¿ãŒããšãã³æŽ»æ§ã®ã»ãšãã©ãå«æãã
ãã©ã¯ã·ãšã³27ã33ãåãããïœâãããããŒ
ã«ã80ïŒ ïŒïŒ¶ïŒïŒ¶ïŒã®æçµæ¿åºŠãŸã§å ãããã
ãŠãã®æº¶æ¶²ãã80ïŒ ïŒïŒ¶ïŒïŒ¶ïŒã®ïœâãããã
ãŒã«ãå«æãã0.1Mã®é ¢é žãããªãŠã ã®æº¶æ¶²
ã§åãã€ãŠå¹³è¡¡åãããªã¯ããœã«ãã»ãžãªãŒã«
ã®ã«ã©ã ïŒ10ÎŒã4.6Ã250mmïŒã«ãã³ããçµãŠ
éããã次ãã§ãã®ã«ã©ã ã0.1Mã®é ¢é žãã
ãªãŠã äžã§ïŒæéã®çŽç·ã®åŸé ã®72ã50ïŒ
ïŒïŒ¶ïŒïŒ¶ïŒã®ãããããŒã«ã§0.25mlïŒåã®æµé
ã§æº¶é¢ããã0.75mlã®ãã©ã¯ã·ãšã³ãéããã
ã€ã³ã¿ãŒããšãã³æŽ»æ§ã¯ïŒã€ã®æ確ãªäž»ããŒã¯
ãšããŠæº¶åºããããããã®ããŒã¯ã¯è£œé ããšã«
å®éçã«å€åããããããã®ããŒã¯ã¯æº¶åºã®é
åºã«åŸã€ãŠÎ±ãβããã³Î³ãšè¡šç€ºãããαâã
ã©ã¯ã·ãšã³ã¯68ïŒ ã®ïœâãããããŒã«ã®æ¿åºŠ
ã§ãβâãã©ã¯ã·ãšã³ã¯66.5ïŒ ã®ïœâãããã
ãŒã«ã§ãγâãã©ã¯ã·ãšã³ã¯65.5ïŒ ã®ïœâãã
ãããŒã«ã§æº¶åºããããã€ã³ã¿ãŒããšãã³ã®æŽ»
æ§ã®åèšã®ååçã¯80ïŒ ããé«ãã€ãã åããŒã¯ãããªããã©ã¯ã·ãšã³ãå¥ã ã«é
ããç¶ç¶ããå·¥çšãçµãŠåã ã«ç²Ÿè£œãããããŒ
ã¯Î³ã¯å€éã§ååšããããŠä»ã®æåããããå
å²ãããããã«æãããã®ã§ããããããã«ç²Ÿ
補ããããã«éžãã ããžãªãŒã«ã«ã©ã ããã®ã
ãŒã¯Î³ãããªããã©ã¯ã·ãšã³54â56ãéããã
ããŠïŒâãããããŒã«ãçäœç©ã®ãããµã³ã§ïŒ
åæœåºããããšã«ãã€ãŠé€å»ããã埮éã®ãã
ãµã³ãçªçŽ æµã®ããšã«é€å»ãããããªãžã³ãšã®
é žããããã1Mãš2Mã®æçµæ¿åºŠã«å ãããã
ãŠãã®æº¶æ¶²ã1Mã®ããªãžã³ããã³2Mã®ã®é ž
ïŒPH4.0ïŒã§åãã€ãŠå¹³è¡¡åãããªã¯ããœã«ã
RPâïŒã«ã©ã ïŒ10ÎŒïœïŒ4.6Ã250mmïŒã«å ã
ãããã®ã«ã©ã ã1Mã®ããªãžã³ïŒãã«ã¡ãŒã
ç·©è¡æ¶²äžã§çŽç·ã®20ã40ïŒ ã®ïŒâãããããŒã«
ã®åŸé ã§ïŒæé以å ã§0.2mlïŒåã®æµéã§æº¶é¢
ããã0.6mlã®ãã©ã¯ã·ãšã³ãéããã掻æ§ã®
äž»ããŒã¯ã¯ã¿ã³ãã¯è³ªã®ããŒã¯ãšäžèŽãããã
ã®ããŒã¯ãããªããã©ã¯ã·ãšã³45ããã³46ïŒ32
ïŒ ãïŒïŒ¶ããããããŒã«ïŒãåãããåæ§ãª
æ¡ä»¶ã§åã¯ãããã°ã©ãåŠçãããã€ã³ã¿ãŒã
ãšãã³ã¯ãã©ã¯ã·ãšã³31ïŒ32ïŒ ãïŒïŒ¶ããã
ãããŒã«ïŒäžã«æº¶åºãããããã®ãã©ã¯ã·ãšã³
ã®æ¯æŽ»æ§ã¯çè¡æž ã¢ã«ããã³ã«é¢ããŠïŒÃ108
åäœïŒmgã§ãããšèšç®ãããããã®ç©è³ªïŒãã©
ã¯ã·ãšã³31ïŒã¯ããã«ä»¥äžã«è¿°ã¹ãã¢ããé žå
æçã«äœ¿çšããããã®é«é液äœã¯ãããã°ã©ã
ã€ãŒã®ãã¿ãŒã³ãèå æ€åºã«ããããšãããã
ã®åçŸæ§ã¯é¡èã§ããã®ãã¿ãŒã³ã®åäžæ§ã蚌
æããããšãã§ããã 粟補ã®çµæãè¡šïŒã«èŠçŽãããæåã®å¹å°ã
ã第ïŒã®RPâïŒã«ã©ã ãŸã§ã®å šäœã®ç²Ÿè£œåºŠã¯
60000ã80000åã§ãã€ããå·¥çšïŒãããžãªãŒã«
å·¥çšãéãã环ç©åçã¯30ã50ïŒ ã®ç¯å²ã§ãã€
ãããã®å·¥çšãè¶ãããšãã€ã³ã¿ãŒããšãã³ã®
ïŒã€ã®ããŒã¯ã®åã ã¯å¥ã ã«ç²Ÿè£œããã ãè¡šã ãè¡šã  ããªã¢ã¯ãªã«ã¢ããã²ã«ã®é»æ°æ³³å ã€ã³ã¿ãŒããšãã³ã®è©ŠæïŒ1.5Ã105åäœïŒã
NaDodSO4ããã³ïŒâã¡ã«ã«ãããšã¿ããŒã«
äžã«ã€ã³ããŠããŒããã次ãã§ã¹ã©ãã»ã²ã«
ïŒslab gelïŒã«å ãããé»æ°æ³³ååŸãã¯ãŒãã
ã·ãŒã»ãã«âïŒCoomassie blueïŒãçšããŠçè²
ãããšåäžã®éã垯ãåŸããããèŠæãã®åå
éã¯æšæºã®ã¿ã³ãã¯è³ªãšæ¯èŒããŠ17500ãšæšå®
ãããã次ãã§ã²ã«ãïŒmmã®èçã«åã€ããå
èçã0.4mlã®0.5Mã®NaHCO3ïŒ0.1ïŒ ã®
NaDodSO4äžã§å質åãããããŠã€ã³ã¿ãŒã
ãšãã³ã®æŽ»æ§ã枬å®ãããæãŠã€ã«ã¹æŽ»æ§ã®å
äžããŒã¯ãåŸãããããã¯äžèšåäžã®ã¿ã³ãã¯
質ã®åž¯ãšäžèŽããã掻æ§ã®ä»ã®ããŒã¯ã¯èŠ³æž¬ã
ããªãã€ãã  ã¢ããé žã®åæ å質ãªäººã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ïŒããŒ
ã¯Î³ïŒã®ã¢ããé žåæãããã«ãªã¬ã¹ã«ãã³
ïŒfluorescamineïŒã®ã¢ããé žåæåšã§ã0.5ã
1ÎŒïœã®çæ¥ã®ïŒnativeïŒã€ã³ã¿ãŒããšãã³ãã
ã³ïŒ³âã«ã«ããã·ã¡ãã«åããã€ã³ã¿ãŒããšã
ã³ã®è©Šæã«ã€ããŠå®æœãããã·ã¹ãã€ã³ïŒã·ã¹
ãã³ã®æ¯ã枬å®ãããããçæ¥ã®ã€ã³ã¿ãŒããš
ãã³ãã«ã«ããã·ã¡ãã«åãã次ãã§6Mã®
HCläžã§éå æ¡ä»¶ïŒ0.1ïŒ ã®ããªã°ãªã³ãŒã«é žïŒ
ã®ããšã§å æ°Žå解ããããããã®æ¡ä»¶äžã§ãã·
ã¹ãã€ã³ã¯ïŒ³âã«ã«ããã·ã¡ãã«åã·ã¹ãã€ã³
ãšããŠæž¬å®ãããããã«å¯Ÿãã·ã¹ãã³ã¯éé¢ã®
ã·ã¹ãã€ã³ãšããŠæž¬å®ããããã¢ããé žã®åæ
å€ãè¡šïŒäžã«èŠçŽãããã¢ããé žå«éã«åºã¥ã
æ¯æŽ»æ§ã¯ïŒãïŒÃ108åäœïŒmgã§ããããšãã
ãã€ãã ãè¡šã ãè¡šã å®æœäŸ ïŒ çœè¡ç ã®æ£è ã®çœè¡çããã®å質ãªäººã®çœè¡ç
ã®ã€ã³ã¿ãŒããšãã³ ãã€ã³ããªã¬ã·ã¹ïŒleukophoresisïŒã«ããã
çœè¡çã®æ£è ïŒæ ¢æ§ã®éªšéæ§ã®çœè¡ç ãCMLïŒ
ã®è¡æ¶²ããåé¢ãã人ã®çœè¡çããã«ãŒã€ã³å«æ
è¡æž äžå«å¹å°äžã§ããŠãŒã«ãã¹ã«ç ãŠã€ã«ã¹ãšå¹
é€ããããšã«ãã€ãŠã€ã³ã¿ãŒããšãã³ã補é ã
ãã5000ã40000åäœïŒmlã®ã€ã³ã¿ãŒããšãã³ã®
å䟡ãæ®éã®è©Šéšã§åŸãããã 粟補æäœã¯æ£åžžã®è¡æ¶²ïŒå®æœäŸïŒïŒããã®ã€ã³
ã¿ãŒããšãã³ã«ã€ããŠèšèŒãããã®ãšåäžã§ã
ãããããŠããªãã³ïŒžâ100ã®ååšäžã®0.5Mã®é ¢
é žã«ããæ²æ®¿ã4Mã®å°¿çŽ äžã®ã»ãã¢ããã¯ã¹ïŒ§
â100ãçšããã²ã«éãPH7.5ã«ããããªã¯ããœ
ã«ãRPâïŒãçšããHPLCããªã¯ããœã«ãã»ãž
ãªãŒã«ãçšããHPLCããã³PH4.0ã«ããããªã¯
ããœã«ãRPâïŒãçšããHPLCãå å«ããŠããã ãªã¯ããœã«ãã»ãžãªãŒã«ã®ã«ã©ã ããã®Î±âã
βâããã³Î³âããŒã¯ãããªããã©ã¯ã·ãšã³ã
å¥ã ã«éãããããŠç¶ç¶ããå·¥çšã§åã ã«ç²Ÿè£œã
ãã ãã©ã¯ã·ãšã³43â46ïŒÎ±âããŒã¯ïŒãéããïœ
âãããããŒã«ãçäœç©ã®ïœâãããµã³ã§ïŒåæœ
åºããããšã«ãã€ãŠé€å»ããã埮éã®ãããµã³ã
çªçŽ æµã®ããšã§é€å»ãããããªãžã³ãšã®é žããã
ãã1Mãš2Mã®æçµæ¿åºŠã«å ãããã®æº¶æ¶²ã1M
ã®ããªãžã³ïŒ2Mã®ã®é žïŒPH4.0ïŒã§åãã€ãŠå¹³è¡¡
åãããªã¯ããœã«ãRPâïŒã«ã©ã ïŒ10ÎŒã4.6Ã
250mmïŒã«éãããã®ã«ã©ã ã1Mã®ããªãžã³ãã«
ã¡ãŒãç·©è¡æ¶²äžã§çŽç·ã®20ã40ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâ
ãããããŒã«ã®åŸé ã§ïŒæé以å ã«0.2mlïŒåã®
æµéã§æº¶é¢ããã0.6mlã®ãã©ã¯ã·ãšã³ãéããã
ã€ã³ã¿ãŒããšãã³ã®æŽ»æ§ã31ã35ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœ
âãããããŒã«ã®ç¯å²ã®åºãããŒã¯ãšããŠæº¶é¢ã
ãããããã®ãã©ã¯ã·ãšã³ãåãããåäžæ¡ä»¶äž
ã«åã¯ãããã°ã©ãåŠçãããã€ã³ã¿ãŒããšãã³
ã®æŽ»æ§ã¯31ïŒ ããã³32ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâãããã
ãŒã«ã«ãããŠïŒã€ã®äž»ããŒã¯ïŒÎ±1ããã³Î±2ïŒäžã«
溶åºããããå°éã®æåã¯34ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâã
ããããŒã«ã«ãã溶åºãããã ãªã¯ããœã«ãã»ãžãªãŒã«ã®ã«ã©ã ããã®ãã©ã¯
ã·ãšã³47ã50ïŒããŒã¯Î²ïŒãéããããŒã¯Î±ã«ã€
ããŠåè¿°ããããã«åŠçãããªã¯ããœã«ãRPâ
ïŒã§ã¯ãããã°ã©ãåŠçãããã€ã³ã¿ãŒããšãã³
ã®æŽ»æ§ã¯ïŒã€ã®äž»ããŒã¯ïŒ32ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâã
ããããŒã«ã«ãããŠÎ²2ããã³34ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâ
ãããããŒã«ã«ãããŠÎ²3äžã«æº¶åºãããããã®å Ž
åãåã¯ãããã°ã©ãåŠçã¯äžå¿ èŠã§ãã€ããã
ãã€ãã®è£œé ã«ãããŠã31ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâãã
ãããŒã«ã§æº¶åºãããβ1ãšè¡šç€ºããããŒã¯ã芳枬
ãããã ãªã¯ããœã«ãã»ãžãªãŒã«ã®ã«ã©ã ããã®ãã©ã¯
ã·ãšã³52â54ïŒããŒã¯Î³ïŒãéãããããŠããŒã¯
αã«ã€ããŠåè¿°ããããã«åŠçãããªã¯ããœã«ã
RPâïŒã§ã¯ãããã°ã©ãåŠçãããã€ã³ã¿ãŒã
ãšãã³æŽ»æ§ã¯ïŒã€ã®äž»ããŒã¯ãããªãã¡ïŒÎ³1ïŒ31
ïŒ ïœâãããããŒã«ãïŒïŒ¶ïŒãγ2ïŒ32ïŒ ïœâãã
ãããŒã«ãïŒïŒ¶ïŒãγ3ïŒ34ïŒ ãïœâãããããŒ
ã«ãïŒïŒ¶ïŒãγ4ïŒ35ïŒ ïœâãããããŒã«ãïŒ
ïŒããã³Î³5ïŒ35.5ïŒ ïœâãããããŒã«ãïŒïŒ¶ïŒ
äžã«æº¶åºãããããã®å Žåãåã¯ãããã°ã©ãåŠ
çã¯äžå¿ èŠã§ãã€ãã ãè¡šã ïŒ åã¯ãããã°ã©ãåŠçåŸ
ïŒïŒ MDBK(ç)现èã«ã€ããŠæ±ºå®ãã掻æ§ïŒæšæºãš
ããŠçã®è¡æž ãçšããŠæž¬å®ããã¿ã³ãã¯è³ª
ã€ã³ã¿ãŒããšãã³ã®åã ã®çš®ãçæããããã®
粟補ã®çµæãè¡šïŒã«èŠçŽããã 皮α2ããã³Î²2ã¯ãªã¯ããœã«ãã»ãžãªãŒã«ã®ã«ã©
ã ã®æº¶åºç¹æ§ã«ãã€ãŠããã«åºå¥ãããïŒÎ±2ã¯68
ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâãããããŒã«ã§ããããŠÎ²2ã¯
66.5ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâãããããŒã«ã§ããããã
溶åºãããã ã€ã³ã¿ãŒããšãã³ã®çš®ã®è©ŠæïŒ1.5Ã105åäœïŒ
ãNaDodSO4ããã³ïŒâã¡ã«ã«ãããšã¿ããŒã«
äžã«ã€ã³ããŠããŒããã次ãã§ã¹ã©ãã»ã²ã«ã«å
ãããé»æ°æ³³ååŸãããŒã¯Î±1ãα2ãβ2ãγ1ãγ2ã
ãã³Î³4ã¯åäžã®åž¯ãäžããããããŒã¯Î²3ãγ3ãã
ã³Î³5ã¯ïŒã€ã®åž¯ãäžãããèŠæãã®ååéã¯ãã¹
ãŠ16000ã18000ã®ç¯å²ã«å ¥ããããã ãβ3ã¯
16500ãš21000ã®åž¯ãäžãããããŠÎ³4ã¯21000ã®åž¯
ãäžããïŒè¡šïŒåç §ïŒã 粟補ãã人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®ãã©
ã¯ã·ãšã³ã®ã¢ããé žåæã¯ããã«ãªã¬ã¹ã«ãã³
ïŒfluorescamineïŒã¢ããé žåæåšãçšã0.5ã1ÎŒ
ïœã®ã€ã³ã¿ãŒããšãã³ã®è©Šæã«ã€ããŠå®æœããã
å æ°Žå解ã6Nã®HCläžã§éå æ¡ä»¶ïŒ0.1ïŒ ã®ããª
ã°ãªã³ãŒã«é žïŒäžã«è¡ã€ããåæã®çµæãè¡šïŒã«
èŠçŽããã ãè¡šã ãã®æ¹æ³ã¯æåæ§ã®ãããªã³ãããŠãã€ã»ã«ã©
ã€ã³ïŒããŒããããªã³ãè «çŽ°èïŒã«å¯Ÿããã€ã³ã¿
ããšãã³ã®çºè²é»å®³äœçšã枬å®ãããã®ã§ããã
åçºè²é»å®³äœçšã¯ãïŒãïŒÃ105ããŠãã€çŽ°èïŒ
mlã«ã€ã³ã¿ããšãã³ãå ãã37âã§ïŒæ¥éå¹é€
åŸã现èæ°ã枬å®ããç¡åŠçå¹é€ç©äžã®çŽ°èæ°ãš
ã€ã³ã¿ããšãã³åŠçå¹é€ç©äžã®çŽ°èæ°ãšãæ¯èŒã
ãŠçŽ°èæ°æžå°ã瀺ããã®ãïŒãšããã ãè¡šã ãè¡šã ïŒ äž¡æ¹ã®åž¯ã®æ··åç©ã®çµæ
粟補ãã人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®ãã
ãããªçš®ïŒ300ãã³ã¢ã«ã6ÎŒïœïŒãéçé žãããª
ãŠã ã®æ°Žæº¶æ¶²ïŒ50ïœïŒãPH8.5ã50ÎŒïŒäžã«æº¶ã
ãããããªãã·ã³ïŒ2ÎŒã®HClãPHïŒãäžã®0.1ÎŒ
ïœïŒãå ãããã®æ··åç©ã37âã§14æéå¹é€ã
ããé ¢é žïŒ5ÎŒïŒãå ãããã®æ··åç©ããªã¯ã
ãœã«ãRPâïŒã«ã©ã ïŒ10ÎŒã®ç²åºŠã4.6Ã250mmïŒ
ã«éããããã®ã«ã©ã ã0.5mlïŒåã«ãããŠïŒæ
é0.1Mã®ã®é žïŒ0.03Mã®ããªãžã³ç·©è¡æ¶²ïŒPHïŒïŒ
äžã§ïŒã40ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâãããããŒã«ã®çŽç·
ã®åŸé ãçšããŠæº¶é¢ãããããããããã«ãªã¬ã¹
ã«ãã³ç£èŠç³»ã«ããæ€ç¥ãããçµæã¯è¡šïŒã«èšèŒ
ãããŠããããããŠïŒ ïœâãããããŒã«ããã³ã
ãŒã¯ã®çžå¯Ÿå€§ããïŒïŒ³ïŒå°ãïŒïŒäžãïŒå€§ïŒã§
è¡šããããŠããã ãè¡šã 粟補ãã人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®çš®
ããã¢ããç³ã50ã100ãã³ã¢ã«ã®ã¬ãã«ã§åå®
ã§ããã¢ããç³åæã«ä»ããããã¹ãŠã®å Žåã«ã
ããŠãã°ã«ã³ãŒã¹ã¢ãã³ããã³ã¬ã©ã¯ããŒã¹ïŒã
ã³ããŒã¹ã¢ãã³ã¯ïŒæ®åºïŒååããå°ã§ãã€ãã
ã»ãšãã©ã®å Žåã«ãããŠãã¢ããç³ã®è¿ãã«æº¶åº
ãããå€ãã®å°ããªããããããã®åæã劚ã
ããããããŠãã¢ããç³ã«å²åœãŠãããããŒã¯ã§
ãããå°ãªããšããã®äžéšã¯ããããã«ãããã®
ã§ããããã æåŸã«ãéå æ°Žå解ïŒback hydrolysisïŒãã
ã³ãã«ãªã¬ã¹ã«ãã³ãçšããã¢ããé žåæãå«ã
ãšããã³ïŒEdmanïŒæ³ã«ããïŒããã¢ã«ã®çŽç²
ãªÎ³2ã€ã³ã¿ãŒããšãã³ã®é åã決å®ããè©Šã¿ã¯ã
ãµã€ã¯ã«ïŒããã³ïŒã«ã€ããŠã¢ããé žãäžããªã
ã€ãã100ãã³ã¢ã«ã®çŽç²ãªÎ³2ã®äººã®çœè¡çã®ã€
ã³ã¿ãŒããšãã³ããã€ã³ã·ã³ã¢ããããããâãŒ
ããã³ã¢ãããããããŒãŒïŒã§37âã§20æéåŠç
ããããçç©åŠç掻æ§ã¯åœ±é¿ãåããããããŠã
ããªãã¢ããé žãåå¿æ¶²äžã«æ€åºãããªãã€ãã
èªå°å¹å°ïŒæå°å¿ é å¹å°ãçœè¡çããã³ããŠãŒã«
ãã¹ã«ç ãŠã€ã«ã¹ïŒã®äžæž ãã¢ãããããããŒãŒ
ã§åŠçããŠããã€ã³ã¿ããšãã³æŽ»æ§ã®æ倱ã¯ã¿ã
ããªãã€ãããã®ããšã¯ã€ã³ã¿ãŒããšãã³ååã¯
粟補åã«ãããããã¯ãããNH2æ«ç«¯ãæãã
ããšã瀺ããå¯Ÿç §ãšããŠç²è£œã€ã³ã¿ãŒããšãã³ãª
ãã³ã«çŽç²ãªã€ã³ã¿ãŒããšãã³ããã³ã€ã³ã·ãŠãª
ã³ã®Î²âéãã¢ãããããããŒãŒïŒãšäžç·ã«ã€ã³
ããŠããŒããããã€ã³ã·ãŠãªã³ã¯ã¢ããé žã®æŸåº
ã«ãã€ãŠãããããã«éšåçã«æ¶åãããããã€
ã³ã¿ãŒããšãã³ã®æŽ»æ§ã®æ倱ã¯èŠ³æž¬ãããªãã€
ãã å®æœäŸ ïŒ (a) ïŒÃ108åäœïŒmgã®æ¯æŽ»æ§ããã€å質ãªäººã®
çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®åèšã§ïŒmgããïŒ
ïŒ ã®æ£åžžãªäººã®è¡æž ã¢ã«ããã³ã®25mläžã«æº¶ã
ããããã®æº¶æ¶²ã现èåŠçãã€ã«ã¿ãŒã«éãã
éãã溶液ãç¡èçã«100åã®å°ã³ãã«åå²
ããŠå ¥ãããåå°ã³ãã¯ãéçµå£æäžã«é©ãã
ïŒÃ106åäœã®çŽç²ãªã€ã³ã¿ãŒããšãã³ãå«æ
ãããå°ã³ãã¯äœ¿çšåå·èµïŒâ20âïŒããããš
ã奜ãŸããã (b) åã ãã»ãŒèªç¶ã«åŸãããæ¯çã§ååšããã
1.5mgã®éããå質ãªã€ã³ã¿ãŒããšãã³ã®çš®Î±1ã
α2ãβ2ãγ1ããã³Î³2ãå«æãããã®è²¯èµããæ··
åç©ãçŽïŒÃ108åäœïŒmgã®æ¯æŽ»æ§ãæããã
ããŠããã«100mgã®æ£åžžãªäººè¡æž ã¢ã«ããã³ã
å«æãã氎溶液ã现èåŠçãã€ã«ã¿ãŒã«éãã
ãããŠéãã溶液ãç¡èçã«100åã®å°ã³ã
ã«åå²ããŠå ¥ãããåå°ã³ãã¯çŽïŒÃ106åäœ
ã®çŽç²ãªéããã€ã³ã¿ãŒããšãã³ãšïŒmgã®äººè¡
æž ã¢ã«ããã³ãå«æããã§ããããéçµå£æäž
ã«é©ããã€ã³ã¿ãŒããšãã³ãå«æããå°ã³ãã¯
䜿çšåå·èµïŒâ20âïŒããããšã奜ãŸããã
ãïŒã€ã®åé¡ã§ãã€ãããããŸã§çšãããŠããæ
è¡ã®äŸã¯ãæ²æ®¿ãã²ã«éãã€ãªã³äº€æã¯ããã
ã°ã©ãã€ãŒãã²ã«é»æ°æ³³åã芪åæ§ã¯ãããã°ã©
ãã€ãŒããã³è¿°ã¹ãã«ã¯å€éããä»ã®æ¹æ³ã§ã
ãã 倩ç¶ã«ç£åºããã極ããŠäœæ¿åºŠã§çç©åŠçè©Šæ
äžã«ååšããé«ååéã®ã¿ã³ãã¯è³ªãåé¢ããã
ãšããèšç»ã¯ãåè¿°ã®æè¡ã®æ€å®ïŒassayïŒãå©
çšããå€å·¥çšæ³ã§ãã€ããå€æ°ã®ãã®ãããªå Žå
ã«ãããŠã極ããŠå€§éã®ç²è£œåºçºç©è³ªãèç©ãã
ã³åŠçããªããŠã¯ãªãããããã«ã¯ç²Ÿè£œåŸã®å·¥çš
ã«ãããŠå€éã®çæç©ã倱ãªãããããé«ãçµè²»
ãšéåžžå€ãã®åŽåãèŠããã åé¡ã®ïŒã€ã®é©åœãªã±ãŒã¹ã¯ã€ã³ã¿ãŒããšãã³
ïŒinterferonïŒãåé¢ããã³ç¹åŸŽã¥ããå€æ°ã®è©Š
ã¿ã®æŽå²ã§ãããã¢ã€ã¶ãã¯ïŒIsaacsïŒããã³ãª
ã³ãã³ãã³ïŒLindenmannïŒã«ããæåã®çºèŠä»¥
æ¥ã20幎ã«ããã€ãŠå šäžçã®ç 究è éã¯ã€ã³ã¿ãŒ
ããšãã³ããããçœè¡çåã§ããããšãŸãç·ç¶èœ
现èåã§ããããšãå質ãªãããããšããŠããã®
ç¹å®ã®çç©åŠçãŸãã¯ååŠçæ§è³ªãç¹åŸŽã¥ãäžã€
åå®ã§ããã®ã«ååãªéã§åé¢ããããšãããã
äžæåã«çµã€ãã ã¢ã€ã¶ãã¯ããã³ãªã³ãã³ãã³ã®ã€ã³ã¿ãŒããš
ãã³ãçšããå ã®ç 究ã«é¢ããç±³åœç¹èš±ç¬¬
3699222å·ã«ãããŠã掻æ§ç©è³ªã®ç²Ÿè£œã¯ç¡«é žã¢ã³
ã¢ããŠã ã®æ²æ®¿ããã³ããã«åŒãç¶ãéæã«éå®
ãããŠããããã®ãããªæ¹æ³ã¯æ¯èŒçéç¹å®çã§
ãããããããŠããã«ãã€ãŠåŸãããçæç©ã¯ãª
ã極ããŠç²è£œç¶æ ã§ããã ã€ã³ã¿ãŒããšãã³ã粟補ããå€å·¥çšæ³ã¯ç±³åœç¹
蚱第3414651å·ã«é瀺ãããŠããããã®å€å·¥çšæ³
ã¯éæ¶è³ªã¢ã«ããâã·ãªã±ãŒãäžã®éžæçåžçã
ãšãŠçŽ ãŸãã¯ããªã·ã¢ããŒãã®æº¶æ¶²ãçšãã溶
é¢ãããã«HCl氎溶液ã次ãã§NaOHãçšããæ
ãŸãªãã¿ã³ãã¯è³ªã®æ²æ®¿ãæ°Žæ··åæ§æº¶åªãããšã
ã°ã¡ã¿ããŒã«ããšã¿ããŒã«ãŸãã¯ã¢ã»ãã³ãçšã
ãã€ã³ã¿ãŒããšãã³ã®å¡©åºæº¶æ¶²ããã®æ²æ®¿ããã
ã³æåŸã«ïŒâãžãšãã«ã¢ãããšãã«âã»ã«ããŒã¹
ã®ãããªé°ã€ãªã³äº€ææš¹èã«ããå溶解ããã€ã³
ã¿ãŒããšãã³ã®ã¯ãããã°ã©ãã€ãŒãçšããŠãã
ã®æ¯æŽ»æ§ããã®å šããã»ã¹ã«ãã6000åã«é«ãã
ãããšç€ºãããã€ã³ã¿ãŒããšãã³ãçæãããäŸ
瀺ãããç¹å®ã®ã€ã³ã¿ãŒããšãã³ã¯ããšã³ãšãµã«
ã®ã€ã³ã¿ãŒããšãã³ã§ãã€ãã ã»ãã®ç²Ÿè£œæ³ã¯ç±³åœç¹èš±ç¬¬3975344å·ã«æ瀺ã
ããŠãããããã§ã¯çŽ°èå¹é€ã®å¹å°ããèªå°ãã
ãç²è£œã®äººã®ç·ç¶èœçŽ°èã®ã€ã³ã¿ãŒããšãã³æº¶æ¶²
ãåºåå¯åºŠåŸé ã®è¶ é å¿åé¢ã«ãã€ãŠç²Ÿè£œãããŠ
ããããã®æè¡ã¯ã»ãã¢ããã¯ã¹ïŒSephadexïŒ
â100ãçšããæ®éã®ã«ã©ã ã°ãããã°ã©ãã€
ãŒã§åŸãããããé«ãåçããã³ç²Ÿè£œãäžããã
ãšã瀺ãããã ã€ã³ã¿ãŒããšãã³ã®ç²Ÿè£œããã³ç¹æ§ã¥ãã«é¢ã
ãæè¿ã®ç§åŠæç®ã¯ã次ã®ããã«èŠçŽããããšã
ã§ããïŒ KnightãE.ãProc.Natl.Acad.Sci.UAS 73ã
520âïŒïŒ1976ïŒïŒ TošrmašãE.T.et al.ãJ.Biol.Chem.251ã4810
âïŒïŒ1976ïŒïŒ BridgenãP.J.et al.ãJ.Biol.Chem.252ã6585
âïŒïŒ1977ïŒïŒ DeMaeyerâGuignardãJ.et al.ãNature
271ã622âïŒïŒ1978ïŒïŒ KawakitaãM.et al.ãJ.Biol.Chem.253ïŒ598
â602ïŒ1978ïŒïŒ BertholdãW.et al.ãJ.Biol.Chem.253ã5206
â11ïŒ1978ïŒïŒ JankowskiãW.J.et al.ãJ.Virology 16ã
1124â30ïŒ1975ïŒïŒ DaveyãM.W.et al.ãJ.Biol.Chem.251ã7620
âïŒïŒ1976ïŒïŒChadhaãK.C.et al.ã
Biochemistry 17ã196â200ïŒ1978ïŒã äžèšã®æç®ã®ããã€ãã¯ããŠã¹ãŸãã¯äººã®ã€ã³
ã¿ãŒããšãã³ãå質ã«ç²Ÿè£œãããšè¿°ã¹ãŠãããã
ã¿ã³ãã¯è³ªã®å質æ§ã®å€å žç蚌æãäžããããŠã
ããããããã¯èšèŒãããŠããçŽç²ãšããããå
åç©ã®æ§è³ªã¯èšèŒãããŠããªãã ã¿ã³ãã¯è³ªã®ç²Ÿè£œã«é«æ§èœæ¶²äœã¯ãããã°ã©ã
ã€ãŒïŒHPLCïŒã䜿çšããããšã¯äžè¬ã«æè¡çã«
ç¥ãããŠããããããã®åèæžã¯ç¹å®çã«ã¿ã³ã
ã¯è³ªã®ç²Ÿè£œã«ãããã€ãªã³äº€æããã³å€§ããæé€
åã®ã«ã©ã ãèšèŒããŠãããããšãã°ã
RegnierãF.E.et al.ãJ.Chromatog.Sci.14ã316
â20ïŒ1976ïŒããã³ChangãS.âH.et al.ãAnal.
Chem.48ã1839â45ïŒ1976ïŒåç §ã éçžïŒrcverse phaseïŒåé ã¯ãããã°ã©ãã€
ãŒã«ããããªã¯ããœã«ãïŒLichrosorbïŒRPâ18
ïŒãªã¯ã¿ãã·ã«çµåã·ãªã«åŸ®ç²åã«ã©ã ïŒã®äœ¿çš
ã¯ãβâãšã³ãã«ãã€ã³ã®ãããªããããã粟補
ããããã«æåãããã®ã§ãããããšãã°ã
RubinsteinãM.et al.ãProc.Natl.Acad.Sci.ã
USA 74ã4969â72ïŒ1977ïŒããæåŸã«ãããŠã¹ã®
Ehrlichè ¹æ°Žçã®è «ç现èããã®ã€ã³ã¿ãŒããšã
ã³ã®ïŒçš®ïŒååéïŒ33000ã26000ããã³20000ïŒ
ã®éšåçç¹æ§ã¥ãã¯ãCabrerãB.et al.ãJ.Biol.
Chem.254ã3681âïŒïŒ1979ïŒã«èšèŒãããŠããã ãŠã·çŽ°èMDBKã®å Žåãæ¯æŽ»æ§0.9Ã108ã4.0
Ã108åäœïŒmgã¿ã³ãã¯è³ªãæãããã现èç³»
AG1732ã®å Žåãæ¯æŽ»æ§ïŒÃ106ã4.0Ã108åäœïŒ
mgã¿ã³ãã¯è³ªãæããååéçŽ16000±1000ãçŽ
21000±1000ã§ãããã¢ããç³åãïŒåååœãïŒ
æ®åºæªæºã§ãããé çžããã³ïŒãŸãã¯ïŒéçžé«é
液äœã¯ãããã°ã©ãã€ãŒã«ãããŠåäžã®ããŒã¯ã
瀺ããšãšãã«ãããã·ã«ç¡«é žãããªãŠã âããªã¢
ã¯ãªã«ã¢ããã²ã«é»æ°æ³³åïŒSDSâPAGEïŒã§å
äžãã³ãã瀺ãå質ã¿ã³ãã¯è³ªã§ããããçœè¡ç
ã€ã³ã¿ããšãã³ãå«æããããã·ã«ç¡«é žãããªãŠ
ã ããã³éã€ã³ã¿ããšãã³æŽ»æ§ã¿ã³ãã¯è³ªå€Ÿéç©
ãå®è³ªçã«å«ãŸãªãããšãç¹åŸŽãšãããããçœè¡
çã€ã³ã¿ããšãã³æåæ§çŸæ£æ²»ççšå»è¬çµæç©ã«
é¢ããã æ¬çºæã®å»è¬çµæç©ã«ãããããçœè¡çã€ã³ã¿
ããšãã³ã¯ããã®å»è¬ãšããŠéèŠãªç©è³ªã®ååŠç
ç¹æ§ã¥ããåããŠå¯èœã«ããçŽãããªã€ã³ã¿ããš
ãã³ãååãªéã§æäŸããæ°èŠè£œé æ¹æ³ã«ããåŸ
ããããæ¬çºæã®çµæç©ã«ãããã€ã³ã¿ãŒããšã
ã³ã®ååŠçç¹æ§ã¥ããå¯èœã«ããããšã¯ããã®ç©
質ã®éçºã«ãããææãªé²æ©ãè¡šããããªããª
ããããã«ãããæ®éã®ããããåææ³ã«ããã
æãã¯ã€ã³ã¿ãŒããšãã³ã¢ããé žé åã«çžåœãã
DNAãåæãããããŠãã®ãããªDNAãé©åœãª
ææ©äœã奜ãŸããã¯ãã¯ããªã¢äžã«ãDNAâçµ
æãæè¡ã«ããå°å ¥ããããšã«ãã€ãŠãã€ã³ã¿ãŒ
ããšãã³ãåæã§ããããã§ããã次ãã§ãçã
ãææ©äœã¯ã€ã³ã¿ãŒããšãã³ãçæããèœåãæ
ããããã¯çºé µæè¡ãå¿çšããŠåæ¥çãªã¬ãã«ã§
åŸæ¥ãŸããªååç©ã®äŸ¿å©ãªæºãæäŸããããã«èŠ
æš¡ã倧ããããããšãã§ããã ã€ã³ã¿ãŒããšãã³ãå質ãªã¿ã³ãã¯è³ªãšããŠè£œ
é ããæ¹æ³ã¯ãäžçŽãªç¶æ ã®ã€ã³ã¿ãŒããšãã³ã®
氎溶液ãã·ã¢ããããã«ãã·ã¯ãããã·ã«ãããš
ãã«ããªã¯ãã«ããªã¯ã¿ãã·ã«ãŸãã¯ã°ãªã»ãªã«
åºãçµåããå€å質ã·ãªã«ã®ãããªãã¯ã¹ã®ç·©è¡
液ã§å¹³è¡¡åããã«ã©ã ã«ãé«é液äœã¯ãããã°ã©
ãã€ãŒïŒHPLCïŒã®æ¡ä»¶äžã«éããŠã€ã³ã¿ãŒããš
ãã³ãã«ã©ã äžã«åžçããããã®åŸãã®ã€ã³ã¿ãŒ
ããšãã³ãå¢å ããåŸé ãŸãã¯æžå°ããåŸé ã®æ°Ž
æ§ã®æ°Žæ··åæ§æº¶åªã§æº¶é¢ãããããŠã€ã³ã¿ãŒããš
ãã³ã溶åºæ¶²ã®éžå®ãã©ã¯ã·ãšã³äžã«é«çŽåºŠã®ç¶
æ ã§åŸãããšãããªãã ã€ã³ã¿ãŒããšãã³ãå質ã®ã¿ã³ãã¯è³ªãšããŠè£œ
é ããæ¹æ³ã®äŸãšããŠã次ã®å·¥çšã®çµã¿åããã
ããªãæ¹æ³ããããããšãã§ããïŒ (A) äžçŽãªç¶æ ã®ã€ã³ã¿ãŒããšãã³ã®æ°Žæº¶æ¶²ãã
ç·©è¡æ¶²ã§å¹³è¡¡åãããªã¯ãã«çµåã·ãªã«ã®ãã
ãªãã¯ã¹ã®ã«ã©ã ã«ãé«æ§èœæ¶²äœã¯ãããã°ã©
ãã€ãŒæ¡ä»¶äžã«éããŠè©²ã€ã³ã¿ãŒããšãã³ã該
ã«ã©ã äžãžåžåããããã®åŸè©²ã€ã³ã¿ãŒããšã
ã³ã該ã«ã©ã ããå¢å ããåŸé ã®æ°Žæ§ã®ç·©è¡ã
ãæ°Žæ··åæ§æº¶åªã§æº¶é¢ãããããŠè©²ã€ã³ã¿ãŒã
ãšãã³ã該溶åºæ¶²ã®éžå®ãã©ã¯ã·ãšã³äžã«é«çŽ
床ã®ç¶æ ã§åŸïŒ (B) å·¥çšïŒ¡ã«ãããŠåŸãããéžã°ããã€ã³ã¿ãŒã
ãšãã³ã®ãã©ã¯ã·ãšã³ããç·©è¡æ¶²ã§å¹³è¡¡åãã
ã°ãªã»ãªã«çµåããã·ãªã«ã®ãããªãã¯ã¹ã®ã«
ã©ã ã«éããŠè©²ã€ã³ã¿ãŒããšãã³ã該ã«ã©ã äž
ãžåžåããããã®åŸè©²ã€ã³ã¿ãŒããšãã³ã該ã«
ã©ã ããæžå°ããåŸé ã®æ°Žæ§ã®ç·©è¡ããæ°Žæ··å
æ§æº¶åªã§æº¶é¢ãããããŠã€ã³ã¿ãŒããšãã³ãæ
確ãªäž»ããŒã¯ãšããŠè©²æº¶åºæ¶²ã®éžå®ãã©ã¯ã·ãš
ã³äžã«é«çŽåºŠã®ç¶æ ã§åŸïŒ (C) å·¥çšïŒ¢ã«ãããŠåŸããã該æ確ãªäž»ããŒã¯ã®
ïŒã€ã«çžåœããã€ã³ã¿ãŒããšãã³ã®éžå®ãã©ã¯
ã·ãšã³ã®ç·©è¡æº¶æ¶²ããç·©è¡æ¶²ã§å¹³è¡¡åãããªã¯
ãã«çµåã·ãªã«ã®ãããªãã¯ã¹ã®ã«ã©ã ã«ãé«
æ§èœæ¶²äœã¯ãããã°ã©ãã€ãŒæ¡ä»¶äžã«éããŠè©²
ã€ã³ã¿ãŒããšãã³ã該ã«ã©ã äžãžåžåãããã
ã®åŸè©²ã€ã³ã¿ãŒããšãã³ã該ã«ã©ã ããæ°Žæ§ã®
ç·©è¡ããæ°Žæ··åæ§æº¶åªã§æº¶é¢ãããããŠã€ã³ã¿
ãŒããšãã³ãåäžã®æ確ãªããŒã¯ãšããŠè©²æº¶åº
液ã®éžå®ãã©ã¯ã·ãšã³äžã«å質ãªã¿ã³ãã¯è³ªã®
ç¶æ ã§åŸããããŠãå¿ èŠã«å¿ããŠãå·¥çšïŒ£ã®æ
äœãå埩ããŠç©¶æ¥µã®å質æ§ãéæããã äžèšã®ãããªå·¥çšã«ããããªã¯ãã«ãŸãã¯ã°ãª
ã»ãªã«å€æ§å€å質ã·ãªã«ã®åŸ®ç²åã®ã«ã©ã ïŒç²åºŠ
ïŒ10ÎŒïŒå¹³åå倧ããïŒ100â«ïŒãšããŠã¯ãã¢ã¡
ãªã«åè¡åœããŠãŒãšãŒã¯å·ãšã«ã ã¹ããªãŒãã®
EMã©ãã©ããªãŒãºïŒEM Laboratories of
ElmsfordãN.Y.ãUSAïŒãããåæšLichrosorb
RPâïŒããã³LichrosorbãžãªãŒã«ãšããŠå ¥æã§
ããååãäŸç€ºã§ãããåçã®ãªã¯ãã«å€æ§å€å
質ã«ã©ã ïŒChromegabond âïŒãšããŠèå¥ã
ããïŒã¯ãã¢ã¡ãªã«åè¡åœããŠãŒãžã€ãŒãžãŒå·ã
ãŒã«ãã³ã®E.Sã€ã³ãã¹ããªãŒãºïŒE.S.
IndustriesãMarltonãN.J.ãUSAïŒããå ¥æã
ãããšãã§ããã åè¿°ã®ã«ã©ã ãå©çšãã䟿å©ãªé«å§æ¶²äœã¯ãã
ãã°ã©ãã€ãŒç³»ã¯ç±³åœç¹èš±ç¬¬4116046å·ã«èšèŒã
ããŠããã ãã®æ¹æ³ãå®æœããå ŽåãäžçŽãªé«ååéã®ã
ãããã®ã奜ãŸããã¯åé¡ã®ã¿ã³ãã¯è³ªã®æ§è³ªãš
é©åããPHã«ãããç·©è¡æ°Žæº¶æ¶²äžã®æº¶æ¶²ãã·ãªã«
ã®ãããªãã¯ã¹ã®ã«ã©ã ã«éããéåžžããã®æäœ
ã¯å å§äžã«ã奜ãŸããã¯çŽ50ãçŽ5000psiïŒ3.4ã
340æ°å§ïŒã®ç¯å²ã«ãããŠå®æœãããã¿ã³ãã¯è³ª
ãã«ã©ã ã«åžçããã次ãã§æ°Žãšæ··åæ§ã®æº¶åªã®
åŸé ãçšããŠéžæçæ¹åŒã§ç¶ç¶ããŠæº¶é¢ãããã
ã®ç®çã«é©ããæ°Žæ··åæ§ã®æº¶åªã®äŸã¯ãã¢ã«ã«ã
ãŒã«ãããšãã°ïœâãããããŒã«ãïŒâãããã
ãŒã«ããšã¿ããŒã«ãã¡ã¿ããŒã«ãïœâãã¿ããŒã«
ãŸãã¯ç°åŒãšãŒãã«ãããšãã°ãžãªããµã³ã§ã
ãã溶é¢æ¶²ã®åå¥ã¯ããã©ã¯ã·ãšã³ã»ã³ã¬ã¯ã¿ãŒ
ã䜿çšããããèªäœç¥ãããæ¹æ³ã«ãããåãã©
ã¯ã·ãšã³äžã®ã¿ã³ãã¯è³ªå«éããé«æ床ã§åäœã
ãããããã¢ãã¿ãŒã§åæã«ç£èŠããããšã«ãã€
ãŠéæããããã®ç®çã«é©åœãªç³»ã¯Bohlen et
al.ãAnal.Biochem.67ã438ïŒ1975ïŒã«é瀺ãããŠ
ããããŸããã¿ãŒã²ããã»ã¿ã³ãã¯è³ªã®ååšãé©
åœãªçç©æ€å®ã«ããç£èŠããããšã奜ãŸããã äž¡æ¹ã®ã«ã©ã ïŒãé çžãåé ã¯ãããã°ã©ãã€
ãŒã®ããã®ã«ã©ã ããã³éçžã¯ãããã°ã©ãã€ãŒ
ã®ããã®ã«ã©ã ïŒãçšãããã©ãããããããå Ž
åã©ã®é åºãéžã¶ãã«ã€ããŠã®æ±ºå®ã¯ã倧éšå粟
補ãã¹ãã¿ã³ãã¯è³ªã®æ§è³ªã«äŸåãããããšã
ã°ã人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®ç¹å®ã®å Žå
ã«ãããŠããŸãäžçŽãªã€ã³ã¿ããšãã³æº¶æ¶²ããPH
7.5ã®ç·©è¡æ¶²ãæãŸããã¯1Mã®é ¢é žãããªãŠã â
é ¢é žç³»ãçšãããªã¯ãã«çµåã·ãªã«ãããªãã¯ã¹
ã«ã©ã ã«éããŠåé¢ããå¢å ããæ¿åºŠåŸé ã®ïœâ
ãããããŒã«ã§æº¶é¢ãã次ãã§éãã掻æ§ãªãã©
ã¯ã·ãšã³ã0.1Mã®é ¢é žãããªãŠã äžã®ã°ãªã»ãª
ã«çµåã·ãªã«ãããªãã¯ã¹ã«ã©ã ã«éããäœäžã
ãïœâãããããŒã«ã®åŸé ã§æº¶é¢ããæåŸã«åé¢
ããã€ã³ã¿ãŒããšãã³æåããªã¯ãã«çµåã·ãªã«
ãããªãã¯ã¹ã«ã©ã ã«ãçŽ4.0ã®ç·©è¡æ¶²ã®PHã奜
ãŸããã¯1Mã®ããªãžã³â2Mã®ã®é žç³»ãçšããŠé
ãããããŠå¢å ããïœâãããããŒã«ã®åŸé ã§æº¶
é¢ããããšã«ãã€ãŠãæè¯ã®çµæãéæãããã
ãšãããã€ãããã®ããã«ããŠã人ã®çœè¡çã®ã€
ã³ã¿ãŒããšãã³ã®ïŒã€ã®å¥ã ã®åœ¢æ ïŒÎ±ãβãã
ã³Î³ïŒã®åã ã¯å質ãªã¿ã³ãã¯è³ªãè¡šããå¥ã ã®
éãããŒã¯ã«åå²ããããšãã§ããã第ïŒã®ãªã¯
ãã«çµåã·ãªã«ãããªãã¯ã¹ã¯ãããã°ã©ãã€ãŒ
å·¥çšã«å¯Ÿããå¹å°ãçšããŠåºçºããå šäœã®ç²Ÿè£œ
ã¯ã60000ã80000åã§ãã€ãããã°ãªã»ããŒã«çµ
åã·ãªã«ãããªãã¯ã¹ã®ã¯ãããã°ã©ãã€ãŒå·¥çš
ãéãã环ç©åçã¯30ã50ïŒ ã®ç¯å²ã§ãã€ãã 人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®ç²Ÿè£œæ³ã®ç¹å®
ã®æ æ§ã«ãããŠãå·¥çšïŒ¢ããã®éžå®ããŒã¯ãã©ã¯
ã·ãšã³ãéããïœâãããããŒã«ãïœâãããµã³
ã§æœåºããŠé€å»ãããããŠåŸ®éã®ïœâãããµã³ã
å·¥çšïŒ£ãžé²ãåã«æ°Žçžããé€å»ããã ãã®æ°èŠæ¹æ³ã«ããåŸãããå質ãªäººã®çœè¡ç
ã®ã€ã³ã¿ãŒããšãã³ã®çš®ã®åã ã¯ãåè¿°ã®HPLC
ã«ã©ã äžã®éãããŒã¯ãšãïŒâã¡ã«ã«ãããšã¿ã
ãŒã«ã®ååšäžã®ããã·ã«ç¡«é žãããªãŠã
ïŒNaDodSO4ïŒããªã¢ã¯ãªã«ã¢ããã²ã«é»æ°æ³³å
äžã®åäžã®çã垯ãšã瀺ããããã®ã²ã«ãæœåºã
ããšãã¿ã³ãã¯è³ªåž¯ãšäžèŽããæãŠã€ã«ã¹æŽ»æ§ã®
åäžã®éãããŒã¯ãåŸãããããã®çŽç²ãªã€ã³ã¿
ãŒããšãã³ã®çš®ã®æ¯æŽ»æ§ã¯ãMDBKã®çã®çŽ°è
ã§çŽ0.9ã4.0Ã108ã®ç¯å²ã§ããããããŠAg1732
ã®äººã®çŽ°è系統ïŒhuman cell lineïŒã§çŽïŒÃ106
ãïŒÃ108ã§ããããšãããã€ããåã€ã³ã¿ããš
ãã³çš®ã®æ¯æŽ»æ§ãè¡šïŒã«ç€ºãããã®æ¯æŽ»æ§ã¯ããŠ
ã€ã«ã¹ã®çŽ°èå€æ§å¹æã«åºã¥ãã€ã³ã¿ããšãã³ã®
æãŠã€ã«ã¹æŽ»æ§ã®æž¬å®æ¹æ³ã§ããCPEåæïŒçŽ°
èå€æ§å¹æé»æ¢æ€å®ïŒã«ãã枬å®ããã çšãã现èç³»ã¯ãŠã·çŽ°èMDBKããã³ãã现
èAG1732ã§ããããããã¯ã€ãŒã°ã«ã®æå°å¿ é
åå°MEMâ10ã«åå±€å¹é€ãããŠãããã®ã§ã
ããçšãããŠã€ã«ã¹ã¯ãããŠã¹ïŒ¬çŽ°èã®åå±€å¹é€
äžã«çè²ãããMEMâ10äžã«åçµä¿åããæ°Žç±
æ§å£å çãŠã€ã«ã¹ïŒVSVïŒã§ããã被éšã€ã³ã¿
ããšãã³ãµã³ãã«ã¯MEMâ10ãçšããŠåžéã
ãã ãã€ã¯ãã¿ã€ã¿ãŒãã¬ãŒãã«ãŸãã€ã³ã¿ããšã
ã³ãµã³ãã«ãæ³šå ¥ããMEMâ10äžã®MDBKã
ãã³AG1732现èç³»ãå ããVSVãæ¥çš®ãããã
ãŠ37âã§16æéã€ã³ããŠããŒããããVSVã«ã
ã现èå€æ§ã50ïŒ æå¶ããã€ã³ã¿ããšãã³æ¿åºŠ
ïŒID50ïŒã1UïŒmlãšãããã®å€ã«åžéåçãä¹
ããæŽã«åæã«æž¬å®ããæšæºã€ã³ã¿ããšãã³ã®
ID50ã瀺ãæ¿åºŠïŒïŒµïŒmlïŒã«åºã¥ãè£æ£ãè¡ãªã€
ãŠã€ã³ã¿ããšãã³ãµã³ãã«ã®æãŠã€ã«ã¹æŽ»æ§ãã€
ãŸãè¡šïŒã«ç€ºãæ¯æŽ»æ§ãåŸããååéã¯è¡šïŒã«èŠ
ãããããã«çŽ16000ã21000ã®ç¯å²ã§ãã€ããã¢
ããé žåæã®çµæã¯è¡šïŒã«èŠçŽãããŠããã ã€ã³ã¿ãŒããšãã³é¡ã¯æãŠã€ã«ã¹æŽ»æ§ãå¶ç掻
æ§ãçºçé»å®³æŽ»æ§ããã³å ç«æå¶æŽ»æ§ã瀺ããã
ãããã®æŽ»æ§ã¯ã人ã®ã€ã³ã¿ãŒããšãã³ãïŒïŒ ã
ãå°ãªãæ¯èŒçç²è£œã®è£œå€ãçšããŠïŒã10Ã106
åäœïŒæ¥ãçšããèšåºã¬ãã«ã«ãããŠããåŸãã
ããæ¬çºæã®ïŒã€ã®é¢ã§ãã粟補ãããå質ãªã€
ã³ã¿ãŒããšãã³é¡ã¯ãåŸæ¥çšããããç²è£œã®è£œå€
ãšåãæ¹æ³ã§æäžéã調æŽããŠæãã¬ãã«ã®ã€ã³
ã¿ãŒããšãã³åäœãäžããããã«ããŠäœ¿çšããã
ãšãã§ãããåã ã®çš®ã¯ãã®ãŸãŸäœ¿çšããããšã
ã§ããæãã¯ãã®ãããªçš®ã®ïŒçš®ä»¥äžã®æ··åç©ã
䜿çšããããšãã§ããããã®ãããªæ··åç©ã¯åé¢
ããçš®ãæãããã«æ··åããããšã«ãã€ãŠåŸãã
ãšãã§ããæãã¯ã€ã³ã¿ãŒããšãã³ã®å¹Ÿã€ãã®çš®
ãååšããããéã€ã³ã¿ãŒããšãã³ã®æŽ»æ§ãªã¿ã³
ãã¯è³ªãååšããªããšããã§ç²Ÿè£œãåæ¢ããçµæ
ç©ãå質ãªã€ã³ã¿ãŒããšãã³ã¿ã³ãã¯è³ªã®æ··åç©
ã§ããããã«ããããšã«ãã€ãŠãåŸãããšãã§ã
ãã ã€ã³ã¿ãŒããšãã³ã®ç£çã®èªå°ãã€ã³ã¿ãŒããš
ãã³ã®åææ¿åºŠããã³ã²ã«éãå«ãã€ã³ã¿ãŒã
ãšãã³ã®åå¥ã¯ãã®åéã§ããç¥ãããæ¹æ³ãçš
ããŠéæããããšãã§ãããäžçŽãªç¶æ ã®ã€ã³ã¿
ãŒããšãã³ã®æ°Žæº¶æ¶²ãçæãããããã®æäœã¯æ¬
çºæã®äžéšåã§ã¯ãªãã æ¬çºæã®çµæç©ã«ãããã€ã³ã¿ããšãã³ã®è£œé
ã以äžã®äŸã«ãããã詳现ã«ç€ºãã å®æœäŸ ïŒ æ£åžžã®æäŸè ïŒdonorïŒããã®å質ãªäººã®çœè¡
çã®ã€ã³ã¿ãŒããšã㳠 ã€ã³ã¿ãŒããšãã³ã®è£œé ã«ãŒã€ã³ïŒ10mgïŒmlïŒãå«æããè¡æž äžå«æ
å°å¿ é å¹å°äžã§ãæ£åžžã®æäŸè ã®è¡æ¶²ããã®ã
ãçœè¡çïŒ107现èïŒmlïŒããããŠãŒã«ãã¹ã«
ïŒNewcastleïŒç æ°ãŠã€ã«ã¹ïŒ15è¡çåéå
äœïŒmlïŒãš16æéå¹é€ããããšã«ãã€ãŠãã€ã³
ã¿ãŒããšãã³ãç£çãããã5000åäœïŒmlã®å¹³
åã®ã€ã³ã¿ãŒããšãã³ã®å䟡ãåŸããçšããæ
äœã¯MogensenãK.E.et al.ãPharmacology
and Therapeutics ã1977ã369â381ïŒ
WheelockãE.F.ãJ.Bacteriol.92ã1415â1421
ïŒ1966ïŒããã³CantellãK.et al.ãAppl.
Microbiol.22ã625â628ïŒ1971ïŒã«å ±åããã
ãã®ãå€å°å€æŽãããã®ã§ãã€ããã€ã³ã¿ãŒã
ãšãã³ã®å䟡ã¯ã现èå€æ§å¹æâé»æ¢æ€å®ã«ã
ã€ãŠæž¬å®ãããã®æ€å®ã¯16æé以å ã§å®æœãã
ããšãã§ããããã¹ãŠã®ã€ã³ã¿ãŒããšãã³ã®å
䟡ã¯åç §åäœïŒmlã§è¡šãããããã¯ãã·ãšã
ã«ã»ã€ã³ã¹ã·ããŠãŒãã»ãªãã»ãã«ã¹ãthe
National Institute of HealthïŒUSAïŒãã«ãã
æäŸããã人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®ã
ãã®åç §æšæºã«å¯ŸããŠè£æ£ããã  ã€ã³ã¿ãŒããšãã³ã®æ¿åºŠããã³åæã®åç» ç¹ã«ç€ºããªããããããããã®æäœã¯ïŒãïŒ
âã§å®æœãããå¹é€ã®çµãã«ãããŠã现èãã
ã³æ®å±ïŒdebrisïŒãäœéé å¿åé¢ïŒ15åã500
ÃïœïŒã«ããé€å»ãããã«ãŒã€ã³ãHClã§PH
4.0ã«é žæ§åããããšã«ãã€ãŠæ²æ®¿ãããïŒæ
éåŸããã®æ··åç©ãé å¿åé¢ïŒ10åã12000Ã
ïœïŒãããããŠãã¬ãããå»æ£ãããäžå±€ïŒ10
ïŒã15ïŒ ïŒïŒ·ïŒïŒ¶ïŒã®ããªã¯ããé ¢é žã«èª¿æŽ
ãããïŒæéåŸãæ²æ®¿ãé å¿åé¢ïŒ10åã
12000ÃïœïŒã«ããéãããããŠ50mlã®0.1Mã®
NaHCO3äžã«å溶解ãããããªãã³Ãâ100
ïŒ0.5ïœïŒãå ãã次ãã§é ¢é žïŒ1.5mlïŒããã
ãŸããªãã滎ã å ããããã®æ··åç©ãïŒâã§ïŒ
æéã次ãã§â20âã§16æé貯èµããã次ãã§
ããã解åããé å¿åé¢ïŒ10åã17000ÃïœïŒ
ããããã¬ãããå»æ£ããäžå±€ãïŒïŒ ã®ããªã¯
ããé ¢é žã«èª¿æŽãããïŒæéåŸããã®æ··åç©ã
é å¿åé¢ïŒ10åã12000ÃïœïŒãããæ²æ®¿ç©ã
éãããããŠïŒmlã®0.5ã¢ã«ã®NaHCO3äžã«å
溶解ããã  ã²ã«é å°¿çŽ ïŒ1.5ïœïŒãã€ã³ã¿ãŒããšãã³ã®æ¿çž®ç©
ã«å ãããããŠãã®æº¶æ¶²ã4Mã®å°¿çŽ ïŒ0.1Mã®
é ¢é žãããªãŠã ã®ç·©è¡æ¶²ã§åãã€ãŠå¹³è¡¡åãã
ã»ããšããã¯ã¹ïŒSephadexïŒïŒ§â100ã®åŸ®çŽ°ç²
åã®ã«ã©ã ïŒ2.6Ã90cmïŒã«éããããã®ã«ã©
ã ã4Mã®å°¿çŽ ïŒ0.1Mã®é ¢é žãããªãŠã ãPH
7.5ã§ã宀枩ã«ãããŠ0.5mlïŒåã®æµéã§æº¶é¢ã
ãã12.5mlã®ãã©ã¯ã·ãšã³ãéãããã€ã³ã¿ãŒ
ããšãã³ã®æŽ»æ§ã¯ãã©ã¯ã·ãšã³19â23äžã«æº¶åº
ãããã  é«æ§èœæ¶²äœã¯ãããã°ã©ãã€ãŒ ã»ãã¢ããã¯ã¹ïŒ§â100ã®è©Šéšã®ãã©ã¯ã·ãš
ã³19â23ãåãããçŽæ¥ãã³ããçµãŠãªã¯ããœ
ã«ãïŒLichrosorbïŒRPâïŒã«ã©ã ïŒ10ÎŒã4.6
Ã250mmïŒã«éããããã®ã«ã©ã ã¯0.01ïŒ
ïŒïŒ¶ïŒïŒ¶ïŒã®ããªãžã°ãªã³ãŒã«ãå«æããïŒã¢
ã«ã®é ¢é žãããªãŠã ç·©è¡æ¶²ïŒPH7.5ïŒã§åãã€
ãŠå¹³è¡¡åãã次ãã§çŽç·ã®æ¿åºŠåŸé ã®ïœâãã
ãããŒã«ã§åäžç·©è¡æ¶²äžã§0.25mlïŒåã®æµéã§
溶é¢ãããïŒæéãïŒã20ïŒ ïŒïŒæéã20ã40
ïŒ ïŒïŒ¶ïŒïŒ¶ïŒãã0.75mlã®ãã©ã¯ã·ãšã³ãéã
ããã€ã³ã¿ãŒããšãã³ã¯ãã©ã¯ã·ãšã³23ã40
ã25ã30ïŒ ïŒïŒ¶ïŒïŒ¶ïŒã®ïœâãããããŒã«ãäž
ã«æº¶åºãããã ã€ã³ã¿ãŒããšãã³æŽ»æ§ã®ã»ãšãã©ãå«æãã
ãã©ã¯ã·ãšã³27ã33ãåãããïœâãããããŒ
ã«ã80ïŒ ïŒïŒ¶ïŒïŒ¶ïŒã®æçµæ¿åºŠãŸã§å ãããã
ãŠãã®æº¶æ¶²ãã80ïŒ ïŒïŒ¶ïŒïŒ¶ïŒã®ïœâãããã
ãŒã«ãå«æãã0.1Mã®é ¢é žãããªãŠã ã®æº¶æ¶²
ã§åãã€ãŠå¹³è¡¡åãããªã¯ããœã«ãã»ãžãªãŒã«
ã®ã«ã©ã ïŒ10ÎŒã4.6Ã250mmïŒã«ãã³ããçµãŠ
éããã次ãã§ãã®ã«ã©ã ã0.1Mã®é ¢é žãã
ãªãŠã äžã§ïŒæéã®çŽç·ã®åŸé ã®72ã50ïŒ
ïŒïŒ¶ïŒïŒ¶ïŒã®ãããããŒã«ã§0.25mlïŒåã®æµé
ã§æº¶é¢ããã0.75mlã®ãã©ã¯ã·ãšã³ãéããã
ã€ã³ã¿ãŒããšãã³æŽ»æ§ã¯ïŒã€ã®æ確ãªäž»ããŒã¯
ãšããŠæº¶åºããããããã®ããŒã¯ã¯è£œé ããšã«
å®éçã«å€åããããããã®ããŒã¯ã¯æº¶åºã®é
åºã«åŸã€ãŠÎ±ãβããã³Î³ãšè¡šç€ºãããαâã
ã©ã¯ã·ãšã³ã¯68ïŒ ã®ïœâãããããŒã«ã®æ¿åºŠ
ã§ãβâãã©ã¯ã·ãšã³ã¯66.5ïŒ ã®ïœâãããã
ãŒã«ã§ãγâãã©ã¯ã·ãšã³ã¯65.5ïŒ ã®ïœâãã
ãããŒã«ã§æº¶åºããããã€ã³ã¿ãŒããšãã³ã®æŽ»
æ§ã®åèšã®ååçã¯80ïŒ ããé«ãã€ãã åããŒã¯ãããªããã©ã¯ã·ãšã³ãå¥ã ã«é
ããç¶ç¶ããå·¥çšãçµãŠåã ã«ç²Ÿè£œãããããŒ
ã¯Î³ã¯å€éã§ååšããããŠä»ã®æåããããå
å²ãããããã«æãããã®ã§ããããããã«ç²Ÿ
補ããããã«éžãã ããžãªãŒã«ã«ã©ã ããã®ã
ãŒã¯Î³ãããªããã©ã¯ã·ãšã³54â56ãéããã
ããŠïŒâãããããŒã«ãçäœç©ã®ãããµã³ã§ïŒ
åæœåºããããšã«ãã€ãŠé€å»ããã埮éã®ãã
ãµã³ãçªçŽ æµã®ããšã«é€å»ãããããªãžã³ãšã®
é žããããã1Mãš2Mã®æçµæ¿åºŠã«å ãããã
ãŠãã®æº¶æ¶²ã1Mã®ããªãžã³ããã³2Mã®ã®é ž
ïŒPH4.0ïŒã§åãã€ãŠå¹³è¡¡åãããªã¯ããœã«ã
RPâïŒã«ã©ã ïŒ10ÎŒïœïŒ4.6Ã250mmïŒã«å ã
ãããã®ã«ã©ã ã1Mã®ããªãžã³ïŒãã«ã¡ãŒã
ç·©è¡æ¶²äžã§çŽç·ã®20ã40ïŒ ã®ïŒâãããããŒã«
ã®åŸé ã§ïŒæé以å ã§0.2mlïŒåã®æµéã§æº¶é¢
ããã0.6mlã®ãã©ã¯ã·ãšã³ãéããã掻æ§ã®
äž»ããŒã¯ã¯ã¿ã³ãã¯è³ªã®ããŒã¯ãšäžèŽãããã
ã®ããŒã¯ãããªããã©ã¯ã·ãšã³45ããã³46ïŒ32
ïŒ ãïŒïŒ¶ããããããŒã«ïŒãåãããåæ§ãª
æ¡ä»¶ã§åã¯ãããã°ã©ãåŠçãããã€ã³ã¿ãŒã
ãšãã³ã¯ãã©ã¯ã·ãšã³31ïŒ32ïŒ ãïŒïŒ¶ããã
ãããŒã«ïŒäžã«æº¶åºãããããã®ãã©ã¯ã·ãšã³
ã®æ¯æŽ»æ§ã¯çè¡æž ã¢ã«ããã³ã«é¢ããŠïŒÃ108
åäœïŒmgã§ãããšèšç®ãããããã®ç©è³ªïŒãã©
ã¯ã·ãšã³31ïŒã¯ããã«ä»¥äžã«è¿°ã¹ãã¢ããé žå
æçã«äœ¿çšããããã®é«é液äœã¯ãããã°ã©ã
ã€ãŒã®ãã¿ãŒã³ãèå æ€åºã«ããããšãããã
ã®åçŸæ§ã¯é¡èã§ããã®ãã¿ãŒã³ã®åäžæ§ã蚌
æããããšãã§ããã 粟補ã®çµæãè¡šïŒã«èŠçŽãããæåã®å¹å°ã
ã第ïŒã®RPâïŒã«ã©ã ãŸã§ã®å šäœã®ç²Ÿè£œåºŠã¯
60000ã80000åã§ãã€ããå·¥çšïŒãããžãªãŒã«
å·¥çšãéãã环ç©åçã¯30ã50ïŒ ã®ç¯å²ã§ãã€
ãããã®å·¥çšãè¶ãããšãã€ã³ã¿ãŒããšãã³ã®
ïŒã€ã®ããŒã¯ã®åã ã¯å¥ã ã«ç²Ÿè£œããã ãè¡šã ãè¡šã  ããªã¢ã¯ãªã«ã¢ããã²ã«ã®é»æ°æ³³å ã€ã³ã¿ãŒããšãã³ã®è©ŠæïŒ1.5Ã105åäœïŒã
NaDodSO4ããã³ïŒâã¡ã«ã«ãããšã¿ããŒã«
äžã«ã€ã³ããŠããŒããã次ãã§ã¹ã©ãã»ã²ã«
ïŒslab gelïŒã«å ãããé»æ°æ³³ååŸãã¯ãŒãã
ã·ãŒã»ãã«âïŒCoomassie blueïŒãçšããŠçè²
ãããšåäžã®éã垯ãåŸããããèŠæãã®åå
éã¯æšæºã®ã¿ã³ãã¯è³ªãšæ¯èŒããŠ17500ãšæšå®
ãããã次ãã§ã²ã«ãïŒmmã®èçã«åã€ããå
èçã0.4mlã®0.5Mã®NaHCO3ïŒ0.1ïŒ ã®
NaDodSO4äžã§å質åãããããŠã€ã³ã¿ãŒã
ãšãã³ã®æŽ»æ§ã枬å®ãããæãŠã€ã«ã¹æŽ»æ§ã®å
äžããŒã¯ãåŸãããããã¯äžèšåäžã®ã¿ã³ãã¯
質ã®åž¯ãšäžèŽããã掻æ§ã®ä»ã®ããŒã¯ã¯èŠ³æž¬ã
ããªãã€ãã  ã¢ããé žã®åæ å質ãªäººã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ïŒããŒ
ã¯Î³ïŒã®ã¢ããé žåæãããã«ãªã¬ã¹ã«ãã³
ïŒfluorescamineïŒã®ã¢ããé žåæåšã§ã0.5ã
1ÎŒïœã®çæ¥ã®ïŒnativeïŒã€ã³ã¿ãŒããšãã³ãã
ã³ïŒ³âã«ã«ããã·ã¡ãã«åããã€ã³ã¿ãŒããšã
ã³ã®è©Šæã«ã€ããŠå®æœãããã·ã¹ãã€ã³ïŒã·ã¹
ãã³ã®æ¯ã枬å®ãããããçæ¥ã®ã€ã³ã¿ãŒããš
ãã³ãã«ã«ããã·ã¡ãã«åãã次ãã§6Mã®
HCläžã§éå æ¡ä»¶ïŒ0.1ïŒ ã®ããªã°ãªã³ãŒã«é žïŒ
ã®ããšã§å æ°Žå解ããããããã®æ¡ä»¶äžã§ãã·
ã¹ãã€ã³ã¯ïŒ³âã«ã«ããã·ã¡ãã«åã·ã¹ãã€ã³
ãšããŠæž¬å®ãããããã«å¯Ÿãã·ã¹ãã³ã¯éé¢ã®
ã·ã¹ãã€ã³ãšããŠæž¬å®ããããã¢ããé žã®åæ
å€ãè¡šïŒäžã«èŠçŽãããã¢ããé žå«éã«åºã¥ã
æ¯æŽ»æ§ã¯ïŒãïŒÃ108åäœïŒmgã§ããããšãã
ãã€ãã ãè¡šã ãè¡šã å®æœäŸ ïŒ çœè¡ç ã®æ£è ã®çœè¡çããã®å質ãªäººã®çœè¡ç
ã®ã€ã³ã¿ãŒããšãã³ ãã€ã³ããªã¬ã·ã¹ïŒleukophoresisïŒã«ããã
çœè¡çã®æ£è ïŒæ ¢æ§ã®éªšéæ§ã®çœè¡ç ãCMLïŒ
ã®è¡æ¶²ããåé¢ãã人ã®çœè¡çããã«ãŒã€ã³å«æ
è¡æž äžå«å¹å°äžã§ããŠãŒã«ãã¹ã«ç ãŠã€ã«ã¹ãšå¹
é€ããããšã«ãã€ãŠã€ã³ã¿ãŒããšãã³ã補é ã
ãã5000ã40000åäœïŒmlã®ã€ã³ã¿ãŒããšãã³ã®
å䟡ãæ®éã®è©Šéšã§åŸãããã 粟補æäœã¯æ£åžžã®è¡æ¶²ïŒå®æœäŸïŒïŒããã®ã€ã³
ã¿ãŒããšãã³ã«ã€ããŠèšèŒãããã®ãšåäžã§ã
ãããããŠããªãã³ïŒžâ100ã®ååšäžã®0.5Mã®é ¢
é žã«ããæ²æ®¿ã4Mã®å°¿çŽ äžã®ã»ãã¢ããã¯ã¹ïŒ§
â100ãçšããã²ã«éãPH7.5ã«ããããªã¯ããœ
ã«ãRPâïŒãçšããHPLCããªã¯ããœã«ãã»ãž
ãªãŒã«ãçšããHPLCããã³PH4.0ã«ããããªã¯
ããœã«ãRPâïŒãçšããHPLCãå å«ããŠããã ãªã¯ããœã«ãã»ãžãªãŒã«ã®ã«ã©ã ããã®Î±âã
βâããã³Î³âããŒã¯ãããªããã©ã¯ã·ãšã³ã
å¥ã ã«éãããããŠç¶ç¶ããå·¥çšã§åã ã«ç²Ÿè£œã
ãã ãã©ã¯ã·ãšã³43â46ïŒÎ±âããŒã¯ïŒãéããïœ
âãããããŒã«ãçäœç©ã®ïœâãããµã³ã§ïŒåæœ
åºããããšã«ãã€ãŠé€å»ããã埮éã®ãããµã³ã
çªçŽ æµã®ããšã§é€å»ãããããªãžã³ãšã®é žããã
ãã1Mãš2Mã®æçµæ¿åºŠã«å ãããã®æº¶æ¶²ã1M
ã®ããªãžã³ïŒ2Mã®ã®é žïŒPH4.0ïŒã§åãã€ãŠå¹³è¡¡
åãããªã¯ããœã«ãRPâïŒã«ã©ã ïŒ10ÎŒã4.6Ã
250mmïŒã«éãããã®ã«ã©ã ã1Mã®ããªãžã³ãã«
ã¡ãŒãç·©è¡æ¶²äžã§çŽç·ã®20ã40ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâ
ãããããŒã«ã®åŸé ã§ïŒæé以å ã«0.2mlïŒåã®
æµéã§æº¶é¢ããã0.6mlã®ãã©ã¯ã·ãšã³ãéããã
ã€ã³ã¿ãŒããšãã³ã®æŽ»æ§ã31ã35ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœ
âãããããŒã«ã®ç¯å²ã®åºãããŒã¯ãšããŠæº¶é¢ã
ãããããã®ãã©ã¯ã·ãšã³ãåãããåäžæ¡ä»¶äž
ã«åã¯ãããã°ã©ãåŠçãããã€ã³ã¿ãŒããšãã³
ã®æŽ»æ§ã¯31ïŒ ããã³32ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâãããã
ãŒã«ã«ãããŠïŒã€ã®äž»ããŒã¯ïŒÎ±1ããã³Î±2ïŒäžã«
溶åºããããå°éã®æåã¯34ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâã
ããããŒã«ã«ãã溶åºãããã ãªã¯ããœã«ãã»ãžãªãŒã«ã®ã«ã©ã ããã®ãã©ã¯
ã·ãšã³47ã50ïŒããŒã¯Î²ïŒãéããããŒã¯Î±ã«ã€
ããŠåè¿°ããããã«åŠçãããªã¯ããœã«ãRPâ
ïŒã§ã¯ãããã°ã©ãåŠçãããã€ã³ã¿ãŒããšãã³
ã®æŽ»æ§ã¯ïŒã€ã®äž»ããŒã¯ïŒ32ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâã
ããããŒã«ã«ãããŠÎ²2ããã³34ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâ
ãããããŒã«ã«ãããŠÎ²3äžã«æº¶åºãããããã®å Ž
åãåã¯ãããã°ã©ãåŠçã¯äžå¿ èŠã§ãã€ããã
ãã€ãã®è£œé ã«ãããŠã31ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâãã
ãããŒã«ã§æº¶åºãããβ1ãšè¡šç€ºããããŒã¯ã芳枬
ãããã ãªã¯ããœã«ãã»ãžãªãŒã«ã®ã«ã©ã ããã®ãã©ã¯
ã·ãšã³52â54ïŒããŒã¯Î³ïŒãéãããããŠããŒã¯
αã«ã€ããŠåè¿°ããããã«åŠçãããªã¯ããœã«ã
RPâïŒã§ã¯ãããã°ã©ãåŠçãããã€ã³ã¿ãŒã
ãšãã³æŽ»æ§ã¯ïŒã€ã®äž»ããŒã¯ãããªãã¡ïŒÎ³1ïŒ31
ïŒ ïœâãããããŒã«ãïŒïŒ¶ïŒãγ2ïŒ32ïŒ ïœâãã
ãããŒã«ãïŒïŒ¶ïŒãγ3ïŒ34ïŒ ãïœâãããããŒ
ã«ãïŒïŒ¶ïŒãγ4ïŒ35ïŒ ïœâãããããŒã«ãïŒ
ïŒããã³Î³5ïŒ35.5ïŒ ïœâãããããŒã«ãïŒïŒ¶ïŒ
äžã«æº¶åºãããããã®å Žåãåã¯ãããã°ã©ãåŠ
çã¯äžå¿ èŠã§ãã€ãã ãè¡šã ïŒ åã¯ãããã°ã©ãåŠçåŸ
ïŒïŒ MDBK(ç)现èã«ã€ããŠæ±ºå®ãã掻æ§ïŒæšæºãš
ããŠçã®è¡æž ãçšããŠæž¬å®ããã¿ã³ãã¯è³ª
ã€ã³ã¿ãŒããšãã³ã®åã ã®çš®ãçæããããã®
粟補ã®çµæãè¡šïŒã«èŠçŽããã 皮α2ããã³Î²2ã¯ãªã¯ããœã«ãã»ãžãªãŒã«ã®ã«ã©
ã ã®æº¶åºç¹æ§ã«ãã€ãŠããã«åºå¥ãããïŒÎ±2ã¯68
ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâãããããŒã«ã§ããããŠÎ²2ã¯
66.5ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâãããããŒã«ã§ããããã
溶åºãããã ã€ã³ã¿ãŒããšãã³ã®çš®ã®è©ŠæïŒ1.5Ã105åäœïŒ
ãNaDodSO4ããã³ïŒâã¡ã«ã«ãããšã¿ããŒã«
äžã«ã€ã³ããŠããŒããã次ãã§ã¹ã©ãã»ã²ã«ã«å
ãããé»æ°æ³³ååŸãããŒã¯Î±1ãα2ãβ2ãγ1ãγ2ã
ãã³Î³4ã¯åäžã®åž¯ãäžããããããŒã¯Î²3ãγ3ãã
ã³Î³5ã¯ïŒã€ã®åž¯ãäžãããèŠæãã®ååéã¯ãã¹
ãŠ16000ã18000ã®ç¯å²ã«å ¥ããããã ãβ3ã¯
16500ãš21000ã®åž¯ãäžãããããŠÎ³4ã¯21000ã®åž¯
ãäžããïŒè¡šïŒåç §ïŒã 粟補ãã人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®ãã©
ã¯ã·ãšã³ã®ã¢ããé žåæã¯ããã«ãªã¬ã¹ã«ãã³
ïŒfluorescamineïŒã¢ããé žåæåšãçšã0.5ã1ÎŒ
ïœã®ã€ã³ã¿ãŒããšãã³ã®è©Šæã«ã€ããŠå®æœããã
å æ°Žå解ã6Nã®HCläžã§éå æ¡ä»¶ïŒ0.1ïŒ ã®ããª
ã°ãªã³ãŒã«é žïŒäžã«è¡ã€ããåæã®çµæãè¡šïŒã«
èŠçŽããã ãè¡šã ãã®æ¹æ³ã¯æåæ§ã®ãããªã³ãããŠãã€ã»ã«ã©
ã€ã³ïŒããŒããããªã³ãè «çŽ°èïŒã«å¯Ÿããã€ã³ã¿
ããšãã³ã®çºè²é»å®³äœçšã枬å®ãããã®ã§ããã
åçºè²é»å®³äœçšã¯ãïŒãïŒÃ105ããŠãã€çŽ°èïŒ
mlã«ã€ã³ã¿ããšãã³ãå ãã37âã§ïŒæ¥éå¹é€
åŸã现èæ°ã枬å®ããç¡åŠçå¹é€ç©äžã®çŽ°èæ°ãš
ã€ã³ã¿ããšãã³åŠçå¹é€ç©äžã®çŽ°èæ°ãšãæ¯èŒã
ãŠçŽ°èæ°æžå°ã瀺ããã®ãïŒãšããã ãè¡šã ãè¡šã ïŒ äž¡æ¹ã®åž¯ã®æ··åç©ã®çµæ
粟補ãã人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®ãã
ãããªçš®ïŒ300ãã³ã¢ã«ã6ÎŒïœïŒãéçé žãããª
ãŠã ã®æ°Žæº¶æ¶²ïŒ50ïœïŒãPH8.5ã50ÎŒïŒäžã«æº¶ã
ãããããªãã·ã³ïŒ2ÎŒã®HClãPHïŒãäžã®0.1ÎŒ
ïœïŒãå ãããã®æ··åç©ã37âã§14æéå¹é€ã
ããé ¢é žïŒ5ÎŒïŒãå ãããã®æ··åç©ããªã¯ã
ãœã«ãRPâïŒã«ã©ã ïŒ10ÎŒã®ç²åºŠã4.6Ã250mmïŒ
ã«éããããã®ã«ã©ã ã0.5mlïŒåã«ãããŠïŒæ
é0.1Mã®ã®é žïŒ0.03Mã®ããªãžã³ç·©è¡æ¶²ïŒPHïŒïŒ
äžã§ïŒã40ïŒ ïŒïŒ¶ïŒïŒ¶ïŒïœâãããããŒã«ã®çŽç·
ã®åŸé ãçšããŠæº¶é¢ãããããããããã«ãªã¬ã¹
ã«ãã³ç£èŠç³»ã«ããæ€ç¥ãããçµæã¯è¡šïŒã«èšèŒ
ãããŠããããããŠïŒ ïœâãããããŒã«ããã³ã
ãŒã¯ã®çžå¯Ÿå€§ããïŒïŒ³ïŒå°ãïŒïŒäžãïŒå€§ïŒã§
è¡šããããŠããã ãè¡šã 粟補ãã人ã®çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®çš®
ããã¢ããç³ã50ã100ãã³ã¢ã«ã®ã¬ãã«ã§åå®
ã§ããã¢ããç³åæã«ä»ããããã¹ãŠã®å Žåã«ã
ããŠãã°ã«ã³ãŒã¹ã¢ãã³ããã³ã¬ã©ã¯ããŒã¹ïŒã
ã³ããŒã¹ã¢ãã³ã¯ïŒæ®åºïŒååããå°ã§ãã€ãã
ã»ãšãã©ã®å Žåã«ãããŠãã¢ããç³ã®è¿ãã«æº¶åº
ãããå€ãã®å°ããªããããããã®åæã劚ã
ããããããŠãã¢ããç³ã«å²åœãŠãããããŒã¯ã§
ãããå°ãªããšããã®äžéšã¯ããããã«ãããã®
ã§ããããã æåŸã«ãéå æ°Žå解ïŒback hydrolysisïŒãã
ã³ãã«ãªã¬ã¹ã«ãã³ãçšããã¢ããé žåæãå«ã
ãšããã³ïŒEdmanïŒæ³ã«ããïŒããã¢ã«ã®çŽç²
ãªÎ³2ã€ã³ã¿ãŒããšãã³ã®é åã決å®ããè©Šã¿ã¯ã
ãµã€ã¯ã«ïŒããã³ïŒã«ã€ããŠã¢ããé žãäžããªã
ã€ãã100ãã³ã¢ã«ã®çŽç²ãªÎ³2ã®äººã®çœè¡çã®ã€
ã³ã¿ãŒããšãã³ããã€ã³ã·ã³ã¢ããããããâãŒ
ããã³ã¢ãããããããŒãŒïŒã§37âã§20æéåŠç
ããããçç©åŠç掻æ§ã¯åœ±é¿ãåããããããŠã
ããªãã¢ããé žãåå¿æ¶²äžã«æ€åºãããªãã€ãã
èªå°å¹å°ïŒæå°å¿ é å¹å°ãçœè¡çããã³ããŠãŒã«
ãã¹ã«ç ãŠã€ã«ã¹ïŒã®äžæž ãã¢ãããããããŒãŒ
ã§åŠçããŠããã€ã³ã¿ããšãã³æŽ»æ§ã®æ倱ã¯ã¿ã
ããªãã€ãããã®ããšã¯ã€ã³ã¿ãŒããšãã³ååã¯
粟補åã«ãããããã¯ãããNH2æ«ç«¯ãæãã
ããšã瀺ããå¯Ÿç §ãšããŠç²è£œã€ã³ã¿ãŒããšãã³ãª
ãã³ã«çŽç²ãªã€ã³ã¿ãŒããšãã³ããã³ã€ã³ã·ãŠãª
ã³ã®Î²âéãã¢ãããããããŒãŒïŒãšäžç·ã«ã€ã³
ããŠããŒããããã€ã³ã·ãŠãªã³ã¯ã¢ããé žã®æŸåº
ã«ãã€ãŠãããããã«éšåçã«æ¶åãããããã€
ã³ã¿ãŒããšãã³ã®æŽ»æ§ã®æ倱ã¯èŠ³æž¬ãããªãã€
ãã å®æœäŸ ïŒ (a) ïŒÃ108åäœïŒmgã®æ¯æŽ»æ§ããã€å質ãªäººã®
çœè¡çã®ã€ã³ã¿ãŒããšãã³ã®åèšã§ïŒmgããïŒ
ïŒ ã®æ£åžžãªäººã®è¡æž ã¢ã«ããã³ã®25mläžã«æº¶ã
ããããã®æº¶æ¶²ã现èåŠçãã€ã«ã¿ãŒã«éãã
éãã溶液ãç¡èçã«100åã®å°ã³ãã«åå²
ããŠå ¥ãããåå°ã³ãã¯ãéçµå£æäžã«é©ãã
ïŒÃ106åäœã®çŽç²ãªã€ã³ã¿ãŒããšãã³ãå«æ
ãããå°ã³ãã¯äœ¿çšåå·èµïŒâ20âïŒããããš
ã奜ãŸããã (b) åã ãã»ãŒèªç¶ã«åŸãããæ¯çã§ååšããã
1.5mgã®éããå質ãªã€ã³ã¿ãŒããšãã³ã®çš®Î±1ã
α2ãβ2ãγ1ããã³Î³2ãå«æãããã®è²¯èµããæ··
åç©ãçŽïŒÃ108åäœïŒmgã®æ¯æŽ»æ§ãæããã
ããŠããã«100mgã®æ£åžžãªäººè¡æž ã¢ã«ããã³ã
å«æãã氎溶液ã现èåŠçãã€ã«ã¿ãŒã«éãã
ãããŠéãã溶液ãç¡èçã«100åã®å°ã³ã
ã«åå²ããŠå ¥ãããåå°ã³ãã¯çŽïŒÃ106åäœ
ã®çŽç²ãªéããã€ã³ã¿ãŒããšãã³ãšïŒmgã®äººè¡
æž ã¢ã«ããã³ãå«æããã§ããããéçµå£æäž
ã«é©ããã€ã³ã¿ãŒããšãã³ãå«æããå°ã³ãã¯
䜿çšåå·èµïŒâ20âïŒããããšã奜ãŸããã
Claims (1)
- ïŒ ãŠã·çŽ°èMDBKã®å Žåãæ¯æŽ»æ§0.9Ã108ã
4.0Ã108åäœïŒmgã¿ã³ãã¯è³ªãæãããã现èç³»
AG1732ã®å Žåãæ¯æŽ»æ§ïŒÃ106ã4.0Ã108åäœïŒ
mgã¿ã³ãã¯è³ªãæããååéçŽ16000±1000ãçŽ
21000±1000ã§ãããã¢ããç³åãïŒåååœãïŒ
æ®åºæªæºã§ãããé çžããã³ïŒãŸãã¯ïŒéçžé«é
液äœã¯ãããã°ã©ãã€ãŒã«ãããŠåäžã®ããŒã¯ã
瀺ããšãšãã«ãããã·ã«ç¡«é žãããªãŠã âããªã¢
ã¯ãªã«ã¢ããã²ã«é»æ°æ³³åïŒSDSâPAGEïŒã§å
äžãã³ãã瀺ãå質ã¿ã³ãã¯è³ªã§ããããçœè¡ç
ã€ã³ã¿ããšãã³ãå«æããããã·ã«ç¡«é žãããªãŠ
ã ããã³éã€ã³ã¿ããšãã³æŽ»æ§ã¿ã³ãã¯è³ªå€Ÿéç©
ãå®è³ªçã«å«ãŸãªãããšãç¹åŸŽãšãããããçœè¡
çã€ã³ã¿ããšãã³æåæ§çŸæ£æ²»ççšå»è¬çµæç©ã
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96325778A | 1978-11-24 | 1978-11-24 | |
| US963257 | 1978-11-24 | ||
| US62374 | 1979-07-31 | ||
| US77710 | 1979-09-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58192896A JPS58192896A (ja) | 1983-11-10 |
| JPS6338330B2 true JPS6338330B2 (ja) | 1988-07-29 |
Family
ID=25506983
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15080379A Granted JPS5594320A (en) | 1978-11-24 | 1979-11-22 | Interferon |
| JP58029632A Granted JPS58192896A (ja) | 1978-11-24 | 1983-02-25 | ã€ã³ã¿âããšãã³ |
| JP62310788A Granted JPS63164897A (ja) | 1978-11-24 | 1987-12-08 | ããçœè¡çã€ã³ã¿ããšãã³ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15080379A Granted JPS5594320A (en) | 1978-11-24 | 1979-11-22 | Interferon |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62310788A Granted JPS63164897A (ja) | 1978-11-24 | 1987-12-08 | ããçœè¡çã€ã³ã¿ããšãã³ |
Country Status (6)
| Country | Link |
|---|---|
| JP (3) | JPS5594320A (ja) |
| AT (1) | AT367769B (ja) |
| HU (1) | HU182500B (ja) |
| MT (1) | MTP857B (ja) |
| MW (1) | MW3379A1 (ja) |
| ZA (1) | ZA796175B (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0245952A (ja) * | 1988-08-05 | 1990-02-15 | Nec Kyushu Ltd | åå°äœåºæ¿ã®åçŽç®± |
| JPH0350337U (ja) * | 1989-09-20 | 1991-05-16 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA796175B (en) * | 1978-11-24 | 1980-11-26 | Hoffmann La Roche | Purified proteins and process therefor |
| EP0058192A1 (en) * | 1980-08-22 | 1982-08-25 | University of Illinois Foundation | Delivery of biologically active components of heterologous species interferon isolates |
| WO1982002834A1 (en) * | 1981-02-17 | 1982-09-02 | Uemura Yahiro | Process for recovering interferon |
| GB2108510B (en) * | 1981-10-03 | 1984-12-12 | Ciba Geigy Ag | Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof |
| CA1190148A (en) * | 1981-10-13 | 1985-07-09 | Samuel S. Asculai | Interferon-containing compositions |
| DE3269727D1 (en) * | 1981-12-07 | 1986-04-10 | Hoffmann La Roche | Crystalline human leukocyte interferon |
| US4534906A (en) * | 1982-11-01 | 1985-08-13 | Genentech, Inc. | Removal of impurities from human leukocyte interferon preparations |
| IL67896A (en) * | 1983-02-13 | 1987-03-31 | Yeda Res & Dev | Two biologically active human gama interferon subtypes,purification thereof and pharmaceutical compositions containing them |
| DE3515336C2 (de) * | 1985-04-27 | 1994-01-20 | Boehringer Ingelheim Int | Verfahren zur Herstellung und Reinigung von â-Interferon |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US963257A (en) * | 1909-03-05 | 1910-07-05 | Alison B Stirling | Superheating-boiler. |
| ZA796175B (en) * | 1978-11-24 | 1980-11-26 | Hoffmann La Roche | Purified proteins and process therefor |
-
1979
- 1979-11-16 ZA ZA00796175A patent/ZA796175B/xx unknown
- 1979-11-21 HU HUHO002197 patent/HU182500B/hu unknown
- 1979-11-21 MW MW3379A patent/MW3379A1/xx unknown
- 1979-11-22 JP JP15080379A patent/JPS5594320A/ja active Granted
- 1979-11-22 MT MT857A patent/MTP857B/xx unknown
- 1979-11-23 AT AT745379A patent/AT367769B/de active Protection Beyond IP Right Term
-
1983
- 1983-02-25 JP JP58029632A patent/JPS58192896A/ja active Granted
-
1987
- 1987-12-08 JP JP62310788A patent/JPS63164897A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0245952A (ja) * | 1988-08-05 | 1990-02-15 | Nec Kyushu Ltd | åå°äœåºæ¿ã®åçŽç®± |
| JPH0350337U (ja) * | 1989-09-20 | 1991-05-16 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH031320B2 (ja) | 1991-01-10 |
| AT367769B (de) | 1982-07-26 |
| MTP857B (en) | 1981-04-29 |
| JPS63164897A (ja) | 1988-07-08 |
| JPS5594320A (en) | 1980-07-17 |
| ZA796175B (en) | 1980-11-26 |
| MW3379A1 (en) | 1981-08-12 |
| JPS6261040B2 (ja) | 1987-12-18 |
| JPS58192896A (ja) | 1983-11-10 |
| ATA745379A (de) | 1981-12-15 |
| HU182500B (en) | 1984-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR830002616B1 (ko) | ëšë°±ì§ì ì ì ë°©ë² | |
| US4503035A (en) | Protein purification process and product | |
| US4289689A (en) | Preparation of homogeneous human fibroblast interferon | |
| Friesen et al. | Purification and molecular characterization of human fibroblast interferon | |
| US4432895A (en) | Monomeric interferons | |
| JPS6338330B2 (ja) | ||
| US4765903A (en) | Purification of monomeric interferon | |
| FI70721C (fi) | Foerfarande foer framstaellning av maenskligt fibroblast-interferon som homigent protein | |
| GB2119383A (en) | Homogeneous human immune interferon and process therefor | |
| US4617378A (en) | Purification of biologically active human immune interferon | |
| WO1988004937A1 (en) | Novel polypeptide having gamma-interferon activity | |
| Rubinstein et al. | [67] Purification and characterization of human leukocyte interferons by high-performance liquid chromatography | |
| KR840001516B1 (ko) | ìžì²Ž ì¬ì ììží¬ ìží°íë¡ ì ì ì¡°ë°©ë² | |
| JPH022390A (ja) | æ°èŠãªããé¡ç²çãã¯ããã¡ãŒãžã³ãããŒåºæ¿å å | |
| HU201100B (en) | Process for large-scale production of high purity human leukocyte alpha interferon with reduced endotoxin content and with improved therapeutic effect | |
| WO1989003225A1 (en) | Purification of monomeric interferon |